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1Liposomes for the 
delivery of the NK3 
receptor agonist 
senktide to the 
central nervous 
system
Introduction
Historically, the first demonstration of 
the presence of a barrier able to limit the 
penetration of circulating compounds 
into the central nervous system (CNS) 
parenchyma was obtained by Paul Ehrlich. 
In a historical experiment he observed 
that dyes (e.g., trypan blue), injected 
intravenously in animals, stained all 
organs with the exception of the brain 
and spinal cord (Ehrlich, 1885). Later, 
Edwin Goldmann, an Ehrlich’s student, 
injecting directly the dyes into the spinal 
fluid of the brain, found that in this case 
the brain became dyed while the rest of 
the body remained dye-free. Thus, he first 
hypothesized that the capillaries of the 
brain were the base of the physiological 
separation between the CNS and the 
rest of the body (Goldmann, 1913). 
This hypothesis was confirmed only in 
the 1960s with the development of the 
electron microscope with which the 
anatomical differences between brain and 
peripheral capillary endothelial cells were 
demonstrated. The so-called Blood Brain 
Barrier (BBB) is primarily composed of the 
brain endothelial cells. Other structures 
such as extracellular base membrane, 
adjoining pericytes, perivascular astrocytes 
and microglia constitute the neurovascular 
unit that is an integral part of the BBB, 
contributing in the formation of a physical 
and metabolic barrier, which seems to be of 
primary importance in the maintenance of 
brain functionality (Fig. 1).
The human brain contains about 100 billion 
capillaries that develop approximately 
650 km and a corresponding surface 
area of about 20 m2 (W Kamphorst, 
2002) (Pardridge, 2003). Brain capillary 
endothelia are very thin cells, roughly 40% 
lower than peripheral capillaries, since the 
luminal and abluminal membranes are 
only separated by about 500 nm or less. 
2The CNS endothelial cells are anatomically 
different from capillary endothelial cells of 
the rest of the body and are characterized 
by the lack of fenestration, the presence 
of only few pinocytotic vesicles (Abbott, 
2005) (Stewart, 2000) and high numerical 
density of mitochondria (Claudio et al., 
1989) (Oldendorf et al., 1977), roughly 
five times greater than in peripheral 
endothelia, necessary for the multiple 
energy-dependent processes supporting the 
nutrient uptake and protection of the brain. 
Adjacent endothelial cells have specialized 
junctional regions: adherens junctions 
(AJs) and tight junctions (TJs), considered 
as the primary physical barrier limiting 
paracellular movement of solutes, ions 
and water (Hawkins and Davis, 2005) 
(Persidsky et al., 2006). In particular, 
TJs (Bernacki et al., n.d.) (Wolburg and 
Lippoldt, 2002) (Jin et al., 2010) are 
located on the most apical site of the cleft 
between brain endothelial cells (Fig. 2) and 
are essentially formed by three different 
integral protein types (occludin, claudins, 
and junctional adhesion molecules [JAMs]. 
TJs are organized in complex parallel, 
interconnected, transmembranal and 
cytoplasmatic strands forming a zipper-like 
seal between adjacent endothelial cells.
The permeability of the brain capillary 
endothelium forming the BBB is about 
two orders of magnitude lower than that 
of endothelia in peripheral organs and 
therefore, the brain is probably one of 
the least accessible organs to circulating 
compounds. Although the BBB tends to 
protect the CNS from endogenous and 
exogenous potentially toxic substances, 
penetration of circulating compounds 
essential for its correct metabolism is also 
required. Several transport routes exist for 
the permeation of different molecules (both 
endogenous and exogenous) across the 
BBB (Fig. 3) (Abbott and Romero, 1996) 
(Pardridge, 2005) (Pardridge, 2007) and, 
in general, they can be classified as: 
- Paracellular aqueous pathway
- Transcellular lipophilic pathway
- Transport proteins or Carrier 
mediated transport (CMT)
- Receptor mediated transcytosis 
(RMT)
- Adsorptive mediated transcytosis 
(AMT)
- Cell mediated transcytosis
Compounds like ethanol, nicotine, 
benzodiazepine, steroid hormones and 
other small lipid soluble substances 
can passively diffuse through the BBB 
following a concentration gradient-
dependent process. These substances enter 
the brain transcellularly by dissolving 
in lipid of the endothelial cell plasma 
membrane. The ability to cross the BBB 
by passive transcellular diffusion is only 
possible for substances having molecular 
weight less than 500 Da, unionized form, 
partition coefficient value (log P) close to 
Fig. 1. Schematic representation of the blood-
brain barrier (BBB) and other components of a 
neurovascular unit
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3Fig. 2. Schematic diagram of the BBB structure 
that comprises the tight and adherens junctions. The 
tight junctions consist of occludin, claudins, and 
junctional adhesion molecules (JAM). The tight 
junctions also consist of several accessory proteins 
necessary to form structural support, including 
the zonula occluden (ZO) proteins, AF6, 7H6, 
cingulin, and others. Most of the tight junction 
components (ZO proteins, claudin, and occludin) 
have the ability to bind to actin cytoskeleton in 
brain endothelial cells. The adherens junctions 
consist of vascular endothelial cadherin (VE-
cadherin) and catenin proteins, provide structural 
integrity and attachment between the cells, and are 
necessary for formation of tight junctions
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Fig. 3. Transport routes across the BBB. Pathways 
“a” to “f ” are commonly for solute molecules; and 
the route “g” involves monocytes, macrophages and 
other immune cells and can be used for any drugs or 
drugs incorporated liposomes or nanoparticles
52 and cumulative number of hydrogen 
bonds not more than 10 (Pardridge, 
2003) (Camenisch et al., 1998) (Chen 
and Liu, 2012)(Cohen and Bangham, 
1972) (van de Waterbeemd et al., 1998).
Receptor-mediated transcytosis 
(RMT)
Different macromolecules can enter the 
intact CNS using a specific transcytotic 
mechanism connected to the presence 
of specific receptors highly expressed in 
specialized areas, rich on clathrin and 
known as coated pits, present on the 
luminal side of the plasma membrane. 
Transcytosis of molecules at the BBB 
is an energy-requiring/ATP-dependent 
transport process (Simionescu et al., 
2002). Molecules such as transferrin, 
albumin, insulin, insulin growth factor, 
low-density lipoproteins, ceruloplasmin, 
and others have a specific receptor on 
the BBB and enter the brain by receptor-
mediated transcytosis (RMT). The first 
RMT step involves the binding of a 
solute (ligand) with its receptor (Fig. 3). 
The formation of the ligand/receptor 
complex triggers the pits invagination 
into the cytoplasm and the formation of a 
clathrin-coated vesicle. This coated vesicle, 
or early endosome, contains the ligand/
receptor complex and moves through the 
cytoplasm of the endothelial cell losing 
its clathrin coating and maturing to 
secondary endosome. After acidification 
of the secondary endosome, the ligand 
will dissociate from the receptor that is 
then recycled to the apical surface. The 
secondary endosome may fuse with a 
lysosome, to form the secondary lysosome, 
or can cross the entire cell and pour out 
its contents to the CNS parenchyma 
(exocytosis) without having been modified 
(Simionescu et al., 2002) (Broadwell et 
al., 1988) (Mellman, 1996).
Transferrin receptor
The human transferrin (Tf ) is a monomeric 
glycoprotein (apo-Tf ) that contains 679 
amino acids with a molecular weight of 
around 80 kDa including two specific high 
affinity Fe(III) binding sites. Transferrin 
can transport one (monoferric Tf ) or two 
(diferric Tf ) iron atoms as well as divalent 
cations, such as gallium or manganese. 
The cellular uptake of iron, required for 
cellular processes and enzymatic reactions, 
occurs through a transcytosis of iron-
loaded Tf mediated by the transferrin 
receptor (TfR) (Pardridge et al., 1987) 
(Moos and Morgan, 2000). However, 
there are still many open questions 
about the actual extent of Tf transcytosis 
through the BBB. Different studies have 
shown that iron uptake by the brain 
exceeds that of Tf (Crowe and Morgan, 
1992) (Morgan and Moos, 2002). The 
TfR is a homodimer (180 kDa) type II 
transmembrane associated glycoprotein 
6consisting of two identical monomers 
(760 amino acids, molecular weight 90 
-- 95 kDa) joined by two intermolecular 
disulfide bonds. Each monomer contains a 
short intracellular N-terminal domain (61 
amino acids), a single-pass transmembrane 
domain (28 amino acids), and a large 
extracellular C-terminal domain (671 
amino acids) that holds the Tf-binding 
site. TfR is ubiquitously expressed at 
low levels on the surface of normal cells 
(Thorstensen and Romslo, 1993) (Gatter 
et al., 1983) (Omary et al., 1980). Its 
expression is elevated, however, on cells 
with a high proliferation rate including the 
basal epidermis and intestinal epithelium 
cells, placental trophoblasts and a variety 
of human cancers cells, (Li and Qian, 
2002) (Sutherland et al., 1981). High 
TfR expression has also been observed on 
nonproliferating cells including endocrine 
pancreas, luminal membranes of the breast, 
hepatocytes, Kupffer cells of the liver, 
tubules of the kidney, and brain endothelial 
cells (Moos and Morgan, 2000) (Gatter 
et al., 1983) (Harel et al., 2011). 
Lactoferrin receptor
Lactoferrin (Lf ), an 80-kDa single-
chain glycoprotein, has been found in 
human various tissues and cells and 
performs multiple physiological functions 
such as facilitating iron absorption, 
modulating immune system, prompting 
embryonic development and inducing 
cell proliferation (Lönnerdal and Iyer, 
1995) (Nichols et al., 1987) (Ward et 
al., 1999). The realization of biological 
activity of Lf depends of the specific 
lactoferrin receptor (LfR) on the surface 
of the target cells. Different researches 
have demonstrated that different target 
tissues and cells express their own LfR 
and that the characteristics and functions 
of LfR vary among different cell types 
(Suzuki and Lönnerdal, 2002) (Suzuki 
et al., 2005). LfR have been reported to 
be anchored to the plasma membrane of 
target cells (small intestine, liver, brain, 
lymphocytes, monocytes, platelets and so 
on) by glycophosphatidylinositol and to 
act as a mediator between Lf and target 
cells (Birgens, 1991) (Cox et al., 1979) 
(Legrand et al., 1992) (Leveugle et al., 
1996) (Maneva et al., 1993) (Ziere et al., 
1993). In general, the biological role of the 
LfR-mediated mechanism has not yet been 
fully elucidated, but it has well known that 
in Parkinson’s disease, neurons have been 
found to accumulate high concentrations 
of human Lf (Leveugle et al., 1996) and it 
was demonstrated that Lf crosses the BBB 
through a brain LfR mediated transcytosis 
mechanism.  
It has been calculated that more than 
98% low molecular weight drugs and 
about 100% high molecular weight 
compounds do not cross the BBB. Natural, 
recombinant or synthesized peptides 
7and proteins, small-interfering RNA 
(siRNA), monoclonal antibodies and 
gene therapeutics with a well-established 
activity to CNS receptors do not readily 
permeate into brain parenchyma due 
to the presence of the BBB (Pardridge, 
2006) (Skaper, 2008). Considering 
that many brain-associated diseases are 
undertreated by effective therapies and 
bearing in mind the narrow number of 
drugs able to cross the BBB, drug transport 
to the CNS is a priority for the academic 
and industrial researchers. Therefore, 
several strategies have been developed for 
delivery therapeutics to the brain, using 
both invasive and noninvasive techniques. 
Invasive methods include disruption of the 
BBB (Deli, 2009) (Garcia-Garcia et al., 
2005) (Neuwelt et al., 1979), convection-
enhanced delivery (Bobo et al., 1994), 
intracerebro and intracerebro-ventricular 
infusion (Chauhan, 2002) (Chamberlain 
et al., 1997) and use of implants (Guerin 
et al., 2004) (Wang et al., 2002). Invasive 
strategy presents many limitations like high 
costs for anesthesia and hospitalization, low 
drug diffusion into the brain parenchyma, 
enhancement of tumor dissemination 
after TJs disruption, lack of efficacy and 
others (Gabathuler, 2010). Noninvasive 
techniques and, in particular, the use 
of nanocarriers have shown superior 
patient compliance, higher efficacy, and, 
in many cases, safety in comparison with 
the invasive ones (Garcia-Garcia et al., 
2005) (Wong et al., 2012) (Invernici et 
al., 2011) (Yang, 2010). Nevertheless, 
design of effective strategies requires a 
deep understanding of the anatomy and 
physiology of CNS barriers, in particular 
the BBB, to achieve a method possessing 
efficacy and safety with regards to its 
impact on the overall protective function 
of the BBB. In the last decade, a great 
deal of interest has been devoted to the 
development of nanocarriers able to deliver 
drugs to the brain. These drug delivery 
systems include different colloidal carriers 
(i.e., micelles, liposomes, nanoparticles etc) 
that have been properly tailored to target 
drugs to the CNS. Among these, liposomes 
have been studied largely as potential 
“magic bullet” capable of circumventing 
the BBB (Barbu et al., 2009) (Celia et 
al., 2011). Liposomes are spherical, self-
closed structures formed by one or several 
concentric lipid bilayers with an aqueous 
phase inside, which were first proposed 
and tested as a drug delivery system in 
the early 1970s. Since then, they have 
been adopted as the vehicle of choice for 
drug delivery and targeting, due to their 
very unique and attractive biological and 
physical chemical properties (Gregoriadis, 
1995). Liposomes are biocompatible 
and can both entrap and protect water-
soluble (hydrophilic) molecules in their 
internal water compartment and water-
insoluble (hydrophobic) into the lipid 
8bilayers. Moreover, they provide a unique 
opportunity to deliver pharmaceuticals 
into cells or even inside individual cellular 
compartments. Indeed, in order to 
facilitate the association and interaction 
with the target site, size, charge and 
surface properties of liposomes can be 
easily changed by simply adding new 
ingredients to the lipid mixture before 
liposome preparation and/or by variation 
of preparation methods (Torchilin, 
2005). For all these reasons liposomes, 
opportunely prepared and functionalized, 
have been considered as nanocarriers for 
brain drug targeting in several pathologies 
after intravenous administrations. To 
deliver liposomes to the brain, they must 
be firstly modified into long circulation 
vesicles by decreasing particle size (< 100 
nm) or by linking polyethylene glycol 
(PEG) chains to their surface. Then, 
they have to be specifically designed to 
release the encapsulated drug in target site 
(Béduneau et al., 2007) (Laquintana 
et al., 2009). To target PEG-liposomes 
specifically to the brain, they have to be 
coupled with various ligands, such as 
transferrin, insulin, lactoferrin etc., whose 
receptors are highly expressed on the BBB. 
The attachment of specific molecules to 
the liposomal surface-granted PEG chains 
allows vesicles to be actively taken up by 
the target cells and, therefore, they can 
enter the brain by an RMT mechanism. 
Essentially, this approach comprises four 
steps:
1) Drug loading (small molecules, peptides, 
gene, etc.) into the liposomes.
2) Conjugation of specific ligands, capable 
of targeting the receptors (transferrin 
receptors [TfR], insulin receptors [IR], 
Lactoferrin receptor [LfR] etc.) at the BBB, 
with the liposomes surface. Endogenous 
ligands (transferrin, lactoferrin) and 
modified endogenous ligands or antibodies 
are used.
3) Transcytosis of the liposomes through 
the BBB, triggered by the ligand binding 
with the receptor, and their accumulation 
into the brain parenchyma.
4) For properly designed liposomal 
nanocarriers, liposomes cross neuronal 
and nuclear neuronal membrane leading 
to their (or their content) accumulation in 
the neuronal cytoplasm or nucleus.
Tf has been used as a homing device 
to target carriers to different cells, in 
particular brain endothelial cells (Ulbrich 
et al., 2009) (van Rooy et al., 2011). 
However, Tf-modified carriers must 
compete for TfR binding site with the 
endogenous Tf present in high amount 
in plasma (2.6 mg/ml), i.e., an amount 
many-fold greater than the dissociation 
constant (KD) of the BBB TfR (5.6 ± 1.4 
nM) (Pardridge et al., 1987). Therefore, 
on the whole, circulating transferring 
heavily saturates the BBB transferrin 
9receptor. For this reason, other molecules 
capable of binding TfR were tested and 
monoclonal antibodies (mAb) have been 
largely studied. Jefferies et al. identified a 
mouse mAb (OX26) that can react in vitro 
and in vivo with rat TfR but cannot block 
Tf binding because it reacts in a binding 
site different from that of Tf (Jefferies et 
al., 1985) (Jefferies et al., 1984). Friden 
et al. first developed a drug delivery system 
for brain release of methotrexate, used as a 
model drug, by means of the mAb OX26 
as a carrier (a vector) (Friden et al., 1991). 
They demonstrated that accumulation 
of radiolabeled methotrexate in the rat 
brain parenchyma, after intravenous 
administration, is greatly enhanced when 
the drug is conjugated to OX-26. The same 
group of researchers used an intraocular 
fetal forebrain septal area tissue transplant 
model to compare the ability of nerve 
growth factor (NGF) alone or conjugated 
to OX26 (OX26-NGF) to protect 
cholinergic neurons in rat (Granholm et 
al., 1994). Huwyler et al. first developed 
immunoliposomes, liposomes with 
antibody attached to their surface, for 
brain delivery of radiolabeled daunomycin 
mediated by the binding of OX26 to the 
rat transferrin receptor (Huwyler et al., 
1996). They demostrated that OX26 
PEG-immunoliposomes determined an 
increase of the permeability of the BBB to 
daunomycin, leading to an increase of the 
brain tissue accumulation, compared to 
free daunomycin. 
Receptor-mediated transcytosis across 
the BBB was also explored by means 
of lactoferrin-conjugated liposomes. As 
the expression of lactoferrin receptor on 
microvessels and neurons is increased 
under certain pathological conditions, 
such as Parkinson’s disease and Alzheimer’s 
disease, the delivery system with lactoferrin 
attachment may be very efficient. Starting 
from these assumptions, Chen et al. 
prepared lactoferrin-modified procationic 
liposomes (by using a cholesterol carbamate 
with a disulfide bond inside) as a potential 
brain drug delivery vector (Chen et al., 
2011) (Chen et al., 2010). The results 
indicated that lactoferrin-modified 
procationic liposomes, in comparison with 
conventional or procationic liposomes, 
improved performance in the uptake 
efficiency.
Senktide and NK3 receptors
The tachykinin peptide family comprises 
three neuropeptides — substance P (SP), 
neurokinin A (NKA) and neurokinin B 
(NKB) — that are widely expressed in 
both the central and peripheral nervous 
system (Ideker et al., 2001). The key 
characteristic of the tachykinins is a highly 
conserved carboxy-terminal aminoacid 
sequence Phe–X–Gly–Leu–Met–NH2, 
where X is either a branched aliphatic 
residue (for NKA and NKB) or an aromatic 
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residue (Ideker et al., 2001). SP, NKA 
and NKB mediate their effects through 
three distinct types of G-protein coupled 
receptors (GPCRs) — the NK1, NK2 and 
NK3 receptors, respectively — that have a 
similar gene structure (Ideker et al., 2001) 
(Kitano et al., 2004). This family of 
receptors comprise a group of recognized 
druggable targets and have recently become 
of interest with regard to schizophrenia. 
Schizophrenia is a severe, disabling and 
lifelong condition that affects 1% of the 
population. It is traditionally characterized 
by positive (psychotic) symptoms, 
such as delusions, hallucinations and 
paranoia, and negative symptoms, such 
as anhedonia, anergia, avolition, flat affect 
and loss of spontaneity. However, cognitive 
impairment (for example, attention 
deficits, working memory deficits and 
deficits in executive function) is now also 
recognized as a key hallmark of the disease 
(Butcher, 2005) (Grabowski, 2004). The 
aetiology of schizophrenia is not known, 
but it is generally accepted that both 
genetic and environmental factors are 
important in the development and clinical 
manifestation of this disorder (Butcher, 
2005). A range of pharmacological 
treatments that are relatively effective in 
providing symptomatic relief are now 
available. Although diverse in nature and 
chemical structure, all currently approved 
antipsychotic drugs share the trait of 
reducing dopaminergic function by at least 
two mechanisms — either dopamine D2 
receptor antagonism or partial agonism 
(Booth and Zemmel, 2004). Many 
evidences suggest the clinical importance 
of NK3 receptor on dopamine function. 
NK3 receptors are almost exclusively found 
in the central nervous system and spinal 
cord (Ideker et al., 2001). In particular, 
they are consistently detected in areas that 
include cortical regions such as frontal, 
parietal and cingulate cortex, various nuclei 
of the amygdala, the hippocampus and, 
most importantly, in midbrain structures 
such as the substantia nigra, ventral 
tegmental area and raphe nuclei (van der 
Greef et al., 2004) (Steuer et al., 2003). 
Data obtained after lesion technique 
indicate that NK3 receptors, more 
precisely, are located exactly on the surface 
of dopamine cells of this areas. (van der 
Greef et al., 2004) (Steuer et al., 2003). 
Over the last years, encouraging preclinical 
and clinical evaluation of NK3 antagonist 
(e.g. osanetant, talnetant) has led to the 
hypothesis that NK3 receptors play an 
important role in the pathophysiology of 
psychoses and conditions characterized by 
an elevated release of DA (Spooren et al., 
2005) (Meltzer and Prus, 2006) (Dawson 
and Smith, 2010). Thus, tachykinin NK3 
receptors have become of interest for the 
treatment of schizophrenia and a large 
number of novel selective NK3receptor 
antagonists have been developed as 
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antipsychotics (Spooren et al., 2005). 
Senktide (S; Succinyl-Asp-Phe-Me-Phe-
Gly-Leu-Met-NH2) is a synthetic peptide 
selective NK3 receptor agonist unable to 
cross the BBB (Fig. 4). 
A directly administration of senktide 
in ventral tegmental area or in the 
substantia nigra by icv originate an intense 
stimulation of NK3 receptors that lead 
to a high dopaminergic response at the 
level of nucleus accumbens shell (Nac 
shell) mediated by D2  receptors and 
subsequently to a reproduction of the same 
pathological condition of several symptom 
of schizophrenia. In particular, it has been 
observed that the responsiveness of NAc 
shell DA to senktide (0.1 nmol/5µl icv) 
is completely abolished by pre-treatment 
with a novel NK3 antagonist (SB222200), 
showing his potential antipsychotic activity 
(De Luca et al., 2011) (Fig. 5).
As already mentioned, senktide is unable 
to cross BBB and this property represents a 
boundary to further neuropharmacological 
studies, but, on the other hand, it is an 
excellent model molecule for the study 
of brain delivery. For these reasons, the 
objective of the present study was the 
development of liposomes to which anti-
transferrin-monoclonal antibodies (TfR-
mAb, Ox26) or lactoferrin was bounded 
to transport senktide across the BBB. 
Senktide was loaded in liposomes for iv 
administration and in vivo microdialysis 
studies were performed to estimate 
the responsiveness of NAc shell DA to 
senktide as a consequence of its delivery 
across BBB. Moreover, in order to study 
the potential antipsychotics activity of the 
NK3 antagonist SB222200, we will study 
his ability to completely abolishes the 
stimulation of DA transmission in NAc 
shell produced by senktide.  
.
Fig. 4. Senktide structure
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Fig. 5. Effector systems of NK3 receptors
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PI, polydispersity index
RMT, receptor mediated trans-cytosis
S, senktide
SL empty stealth liposomes
SLOx26 OX26 conjugated 
Immunoliposomes 
SLLf Lactoferrin conjugated liposomes
SSL Stealth liposomes
TEM, Transmission Electron Microscopy
Tf, transferrin
TfR, transferrin receptor
ZP, zeta potential
Materials & methods
Materials
Distearoylphosphatidylcholine (DSPC) 
and polyethylene glycol-distearoylphosp
hatidylethanolamine-(DSPE-PEG) were 
purchased from Lipoid (Ludwigshafen, 
Germany). DSPE-PEG-maleimide was 
purchased from NOF corporation (Tokyo, 
Japan). Cholesterol, 2-iminothiolane 
(Traut’s reagent), Lactoferrin, Sepharose 
CL-4B, 10 nm gold-labeled rabbit 
antimouse secondary antibody, acetonitrile 
and uranyl acetate were purchased from 
Sigma (Milan, Italy). Centriprep-30 
(molecular weight cut-off: 30,000) 
concentrators were from Amicon (Billerica, 
Massachusetts). Anti-rat transferrin 
receptor OX26 mAb was from AbD 
Serotec (Kidlington, UK). Senktide was 
from Tocris Bioscience (Bristol, UK). The 
NK3 antagonist SB222200  was provided 
by Roche ( Basel, Switzerland).
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Liposomes preparation
Liposomes were prepared using the thin-
film hydration method. DSPC (5.2 
µmol), cholesterol (4.5 µmol), DSPE-PEG 
(0.3 µmol) and, for the preparation of 
immunoliposomes (SLOx26) or lactoferrin 
conjugated liposomes (SLLf ), DSPE-PEG-
maleimide (0.18 µmol), were dissolved 
in a chloroform/methanol (2:1) mixture. 
The solvent was evaporated under reduced 
pressure at room temperature. The vacuum 
was applied for 6 h to ensure total removal 
of solvent trace. The obtained lipid film was 
hydrated under mechanical stirring with 
a 100 µg/ml senktide phosphate buffer 
solution at 65°C. Obtained liposomes 
were subjected to five freeze-thaw cycles 
(-80°C, 65°C) and extruded through a 
200 nm (9 cycles), 100 nm (9 cycles) and 
50 nm (5 cycles) pore size polycarbonate 
membrane using an Avanti Mini-Extruder 
(Avanti Polar Lipids, Alabaster, AL, USA). 
For the preparation of immunoliposomes 
(SLOx26), OX26 antibody was thiolated 
by reaction with iminothiolane. In a 
typical experiment, iminothiolane (32 
µg; 0.23 µmoles) is reacted with OX26 
(1 mg; 0.0058 µmoles) in 3 mL of borate 
buffer solution adjusted at pH 8.1. 4mM 
solution of EDTA is added to chelate 
divalent metals eventually present in 
the solution. The mixture is stirred for 2 
hours at room temperature. Thiolated 
OX26 solutions were concentrated and 
the buffer exchanged with phosphate 
buffer solution using a Centriprep-30 
concentrator (molecular weight cut-off: 
30,000). Finally, purified thiolated OX26 
antibody were incubated with maleimide 
grafted liposomes overnight at room 
temperature. Lactoferrin conjugated 
liposomes (SLLf ) were prepared with the 
same method. Thiolated Lf was prepared 
using a iminothiolane and lactoferrin 
concentration of 0,09 µmol. SLOx26 and 
SLLf were separated from senktide and 
free mAb or Lf by a Sephadex CL-4B gel 
filtration chromatography using phosphate 
buffer as eluent. 
Liposomes characterization 
(phisycochemical 
characterization: mean size, ZP, 
PI)
The average diameter, polydispersity 
index (PI) and zeta potential of the 
samples were determined by Photon 
Correlation Spectroscopy (PCS) using a 
Zetasizer nano-ZS (Malvern Instrument, 
UK). Samples were backscattered by a 
helium-neon laser (633 nm) at an angle 
of 173° and a constant temperature of 
25°C. The instrument systematically and 
automatically adapts to the sample by 
adjusting the intensity of the laser and 
the attenuator of the photomultiplier, 
thus ensuring reproducibility of the 
experimental measurement conditions. 
The PI was used as a measure of the width 
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of the size distribution. PI less than 0.2 
indicates a homogenous and monodisperse 
population. Zeta potential was estimated 
using the Zetasizer nano-ZS by means 
of the M3-PALS (Phase Analysis Light 
Scattering) technique, which measures 
the particle electrophoretic mobility in 
a thermostated cell. All the samples were 
analyzed 24 h after their preparation.
Incorporation efficiency
Incorporation efficiency (E%), expressed 
as the percentage of the encapsulated drug 
respect to the amount of senktide initially 
used in the liposomes preparation, was 
determined by liquid chromatography 
coupled to mass spectrometry (LC/MS, 
see LC/MS analysis paragraph). Senktide 
incorporated into liposomes was separated 
from unincorporated senktide by gel 
filtration (Sepharose CL-4B). Senktide LC/
MS analysis was performed after vesicles 
disruption using methanol.
Morphological characterization
Transmission electron microscopy (TEM) 
of liposomes and immunoliposomes was 
performed. Liposomes were deposited 
for 2 min on formvar coated 200 mesh 
copper grids and negatively stained with 
2,5% uranyl acetate for 2 min, washed 
with water, drained and observed at 80 
kV with a TECNAI 12 (FEI) TEM. 
For demonstration of antibody presence 
on the immunoliposome surface, 
immunoliposomes were allowed to react 
‘‘on grid’’ with 10 nm gold-labeled rabbit 
antimouse secondary antibody for 120 
min. Excess of antibody was washed with 
PBS, immuliposomes were then stained 
and observed as below.
In vivo brain microdialysis 
experiments
Animals and experimental groups
Male Sprague-Dawley rats (Harlan, Italy) 
weighing 250-275g upon arrival, were 
housed in groups of six per cage with 
standard food (MIL topi e ratti, GLP diets, 
Stefano Morini, S. Polo D’Enza, RE, Italy) 
and water ad libitum, for at least one week 
in the central animal room, under constant 
temperature (23 °C), humidity (60%) 
and a 12 h light/dark cycle (light from 8 
a.m. to 8 p.m.). Animals were divided 
into 10 experimental groups: 1) S iv (0.1 
mg/kg); 2) S icv (0.2 nmol/5µl); 3) SL 
(empty stealth liposomes, 0.1 ml/kg iv); 
4) SSL (S loaded stealth liposomes, 0.1 
mg/kg iv); 5) SLOx26 (S loaded OX26 
conjugated immunoliposomes, 10 µg/kg 
iv); 6) LOx26 (empty OX26 conjugated 
immunoliposomes, 1 ml/kg iv); 7) SB 
(SB22220, NK3 receptor antagonist, 3 
16
mg/kg iv); 8) SB + SLOx26 (3 mg/kg iv + 
10 µg/kg iv); 9) SLLf (S loaded lactoferrin 
conjugated liposomes, 10 µg/kg iv); 10) 
animals for senktide distribution study in 
brain and liver tissue. All procedures and 
experiments were carried out in an animal 
facility according to Italian (D.L. 116/92 
and 152/06) and European Council 
directives (609/86 and 63/2010) and in 
compliance with the approved animal 
policies by the Ethical Committee for 
Animal Experiments (CESA, University 
of Cagliari) and the Italian Department of 
Health.
Surgery
Rats were anaesthetized with 300 mg/kg 
intraperitoneal (ip) of chloral hydrate (Carlo 
Erba, Italy) and placed in a stereotaxic 
apparatus. The skull was exposed and a 
small hole drilled to expose the dura on one 
side; this was removed and a microdialysis 
probe was inserted vertically at the level of 
the NAc shell (A+2.2, L+1.0 from bregma, 
V-7.8 from dura) according to the atlas of 
Paxinos and Watson (De Luca et al., 2012) 
(Paxinos and Watson, 1998) (Fig. 6). In 
the same session, a polyethylene catheter 
was inserted in the right jugular vein; one 
group was also implanted with icv cannula 
at the level of the lateral ventricle (A-0.9; 
L+1.5 from bregma, V-3.2 from dura).
Analytical procedure
On the day following surgery, the probes 
were connected to an infusion pump 
and perfused with Ringer’s solution (147 
mM NaCl, 4 mM KCl, 2.2 mM CaCl2) 
at a constant rate of 1 µl/min. Dialysate 
samples (10 µl) were taken every 10 min 
and injected into an HPLC equipped 
with a reverse phase column (LC-18 DB, 
15 cm, 5 µm particle size, Supelco) and a 
coulometric detector (ESA, Coulochem II, 
Bedford, MA) to quantify DA. The first 
electrode of the detector was set at + 130 
mV (oxidation) and the second at - 175 
mV (reduction). The composition of the 
mobile phase was: 50 mM NaH2PO4, 0.1 
mM Na2-EDTA, 0.5 mM n-octyl sodium 
sulfate, 15% (v/v) methanol, pH 5.5. The 
sensitivity of the assay for DA was 5 fmol/
sample.
Histology
At the end of the in vivo microdialysis 
experiments, rats were transcardially 
perfused with 50 ml saline and 150 ml of 
a 10% formaldehyde solution. The probes 
were removed and the brains were cut by a 
vibratome in serial coronal slices and the 
location of the probes was reconstructed 
and referred to the atlas of Paxinos and 
Watson (1998) (Paxinos and Watson, 
1998).
Senktide tissue distribution 
study  
The brain and liver were post-mortem 
	  
Fig. 6. Schematic representation of the localization 
of microdialysis probes dialysing portion within 
the NAc shell and core (according to Paxinos and 
Watson, 1998). CPU, Caudate putamen; co, sh, 
core and shell of the NAc; cc, corpus callosum; ca, 
anterior commisure
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collected from treated animals and kept at 
-80° C until analysis. 0.5 g of sample were 
individually weighed, placed in a falcon 
tube and homogenized in 5 mL phosphate 
buffer at pH 7.4 by means of an ultrasonic 
disruptor. The matrix thus obtained was 
acidified with 2 mL perchloric acid (0.1 M) 
centrifuged at 13000 rpm and the surnatant 
was filtered with Acrodisc Syringe Filters 
with 0,45 µm PTFE Membrane (Life 
Science) and subjected to chromatographic 
analysis by LC/MS.
LC/MS analysis 
The amount of encapsulated senktide 
as well as brain and liver levels after 
in vivo experiments were determined 
by liquid chromatography coupled to 
mass spectrometry (LC/MS). A Varian 
1200 L triple-quadrupole tandem mass 
spectrometer (Palo Alto, CA, USA) 
together with a ProStar 410 autosampler, 
two ProStar 210 (Varian Inc., CA, USA) 
pumps and a 1200 L triple-quadrupole 
mass spectrometer (Varian Inc., CA, 
USA) was used with an electrospray 
ionization source (ESI). The Varian MS 
workstation version 6.7 software was 
used for data acquisition and processing. 
Chromatographic separation was 
performed on a Phenomenex Column 
Synergi MAX-RP 80A (4.6 mm × 150 
mm i.d., 4 µm) (Phenomenex Italy, 
Castel Maggiore (Bo), Italy). The mobile 
phase consisted of (A) acetonitrile 50% 
(v/v) containing 0.1% trifluoroacetic 
acid and (B) double distilled water 50% 
(v/v) containing 0.1% trifluoroacetic acid 
reaching 80% of A in 15 min. The mobile 
phase, previously degassed with high-
purity helium, was pumped at a flow rate 
of 0.3 ml/min, the injection volume was 10 
µl and total run time 15 min. Liposomes 
preparation were diluted ESI was operated 
in the positive ion mode. The electrospray 
capillary potential was set at 149V, the 
needle at 5000V, and the shield at 600V. 
Nitrogen, at 48 mTorr and 375°C, was 
used as a drying gas for solvent evaporation. 
Full-scan spectrum was obtained in the 
ranges of 100-1000 atomic mass unit 
(amu) for senktide, scan time of 0.75 amu, 
scan width of 0.70 amu, and detector at 
1450V. For ESI the atmospheric pressure 
ionization (API) housing was kept at 50°C. 
Senktide was detected in the single ion 
monitoring mode (SIM) observing the 
sodium and potassium adducts at mass 
865 and 881 m/z respectively. The scan 
time was 1 sec, and the detector multiplier 
voltage was set to 2000V, with an isolation 
width of m/z 1.2 for quadrupole 1. 
Statistics
Statistical analysis was carried out by 
Statistica for Windows. Difference in the 
levels of extracellular DA between groups 
were analysed by ANOVA analysis of 
variance for repeated measures. Results 
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from treatments showing significant 
overall changes were subjected to post hoc 
Tukey’s test. Basal values were the means of 
three consecutive samples differing by no 
more than 10%. Difference in the tissue 
distribution of senktide were analysed by 
T-test. It was determined that p<0.05 was 
statistically significant.
Results and discussion
Liposome preparation and 
characterization 
Liposomes (see Fig.7 for schematic 
representation) were prepared using the 
film hydration method and repeated 
extrusion through 200, 100 and 50 nm 
pore size polycarbonate membrane. Six 
different formulations have been prepared 
using the components reported in Table 1. 
SSL were prepared using (DSPC), DSPE-
PEG and cholesterol. For the preparation 
of SLOx26 and SLLf part of DSPC has 
been substituted with the lipid linker 
DSPE-PEG maleimide. The introduction 
of DSPE-PEG maleimide in the vesicle 
structure is required to link the homing 
device (OX26 or Lf ) to the liposomes 
bilayer. In order to bind the linker with a 
thioether bond, OX26 and Lf have been 
thiolated. In the case of OX26 a mAb/
iminothiolane 1:40 molar ratio has been 
used to ensure an average thiolation of one 
primary ammine per mAb (Huwyler et al., 
1996). As previously reported, thiolation 
of OX26 does not interfere with TfR 
recognition (Kang et al., 1995). Since the 
maleimide group slowly hydrolyses when 
in contact with water, it was essential to 
proceed for the preparation of SLOx26 and 
SLLf quickly.  The senktide encapsulation 
efficiency (E%) was determined by LC/MS 
after separation of unincorporated senktide 
by gel filtration.  The introduction of 
OX26 mAb or Lf little influence the E% 
compared to that of SSL. Reproducible E% 
values of 34.5±2.2, 32.5±2.5 and 30.3±2.1 
were obtained for SSL, SLOx26 and SLLf 
respectively. 
Formulations
Components SSLmol
SL
mol
LOx26
mol
SLOx26
mol
SLLf 
mol
LLf
mol
DSPC 5.02 5.02 5.20 5.20 5.20 5.20
Cholesterol 4.50 4.50 4.50 4.50 4.50 4.50
DSPE- PEG 0.30 0.30 0.30 0.30 0.30 0.30
DSPE- PEG 
Maleimide - - 0.18 0.18 0.18 0.18
Senktide 0.12 - 0.12 -
-
0.12 
OX26 - - 0.002 0.002 - -
-
Lactoferrin - - - 0.09 0.09
Table 1. Liposomes composition. SSL (senktide 
loaded stealth liposomes), SL (empty Stealth 
liposomes), SLOx26 (senktide loaded OX26 
conjugated liposomes), LOx26 (empty OX26 
conjugated liposomes),  SLLf (senktide loaded 
lactoferrin conjugated liposomes), LLf (empty 
lactoferrin conjugated liposomes)
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Lactoferrin
Lactoferrin
SSL
SLOx26SLLf
OX26 Mab
OX26 Mab
Target: Transferrin receptor TfRTarget: Lactoferrin receptor LfR
PEG
Senktide
Fig.7. Schematic representation of liposomes
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In table 2 the mean diameter, 
polydispersion index and Z potential of 
different formulations are reported. All 
six liposome formulations showed a mean 
diameter around 120 nm, as determined 
by Photon Correlation Spectroscopy 
(PCS). It is important that the liposomes 
mean diameter do not exceed this value 
in order to ensure a good circulation of 
the nanocarriers through the tighter rat 
brain blood vessels which is about 5 µm 
and to prevent obstructions (Villringer 
et al., 1994). Polydispersion index 
(0,131 for SSL, 0,134 for SLOx26 and 
0,185 for SLLf ) demonstrated a good 
monodisperse size distribution for all the 
formulations. Slightly negative Z potential 
values (near zero) for the three types of 
liposomes suggesting a modest stability. To 
overcome possible liposomes aggregations, 
formulations were tested 24h after their 
preparation. In table 2 the mean diameter, 
polydispersion index and Z potential of 
empty liposomes are also reported. Empty 
liposomes showed a smaller diameter 
compared to that of corresponding loaded 
formulations. Polydispersion index and Z 
potential values of empty liposomes were 
similar of that of loaded formulations.
TEM analysis (Fig.8) was performed to 
investigate the liposomes morphology, to 
confirm their mean diameter determined 
by Photon Correlation Spectroscopy (PCS) 
and to verify the linkage between OX26 
and the liposomes bilayer. Unfortunately, 
in normal conditions, surface-linked 
OX26 mAb is not detected by electron 
microscopy, so we use an anti IgG 
secondary antibody carrying at its distal 
end a 10 nm gold nanoparticles. This 
second antiboby specifically react which 
anti-transferrin-monoclonal antibodies 
OX26. After negatively stain with uranyl 
acetate and after purification, 10 nm gold 
nanoparticle appear in micrography like 
a small, spherical shadows attached onto 
liposome surface indicating the presence 
of OX26 and his occurred bond with the 
liposomes surface.
 
SSL
SLOx26
 
SLLf 
SL  
LOx26
 LLf  
Mean size (nm)
129,3 ± 5,9  
120,6 ± 2,1  
123,7 ± 4,9  
112,3 ± 3,6  
109,7 ± 1, 8  
117,8  ± 7,2  
PI 
0,131 ± 0,005
 
0,134 ± 0,018
 
0,185 ± 0,024
0,115 ± 0,037
0,177 ± 0,002
0,163 ± 0,088
ZP 
- 2,02 ± 0,24
- 0,85 ± 1,52
- 3,62 ± 0,99
- 1,37 ± 0,83
- 2,22 ± 0,65
- 0,94 ± 0,37
Table 2. Liposome physicochemical characterization 
of SSL (senktide loaded stealth liposomes), SL 
(empty Stealth liposomes), SLOx26 (senktide 
loaded OX26 conjugated liposomes),  LOx26 
(empty OX26 conjugated liposomes),  SLLf 
(senktide loaded lactoferrin conjugated liposomes), 
LLf (empty lactoferrin conjugated liposomes)
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In vivo brain microdialysis
Basal values of DA in the NAc shell were: 
52±6 (N=34). Values were expressed as 
fmoles/10-µl sample (mean±SEM).
Responsiveness of NAc shell 
DA to senktide delivered by 
liposomes conjugated to mAb 
OX26
Figure 9 shows the effect of senktide 
administration by liposome conjugated 
to OX26 (SLOx26, 10 µg/kg iv) on NAc 
shell dyalisate DA. The figure also shows 
the comparison between SLOx26 and 
the administration of senktide iv, icv, by 
stealth liposome and the effect of empty 
stealth liposome and empty LOx26. 
Two-way ANOVA showed a significant 
effect of group [F(5,21)=11.85, p<0.001] 
and a significant group x time interaction 
[F(90,378)=1.5, p<0.005]. Tuckey’s post hoc 
test revealed differences between senktide 
administered icv and by LOx26 and all the 
other groups.  Interestingly, the DA increase 
observed after SLOx26 administration 
overlapped the increase induced by the icv 
infusion of S. 
Blockade of NAc shell DA 
increase senktide-mediated 
by NK3 receptor antagonist 
(SB222200)
Figure 10 shows the blockade of the 
effect of senktide on dialysate DA by the 
NK3 receptor antagonist SB222200 (SB, 
3 mg/kg iv). Two-way ANOVA showed 
a significant effect of group [F(2,13)=16.6, 
p<0.001] and a significant group x time 
interaction [F(36,234)=1.7, p<0.005]. 
Tuckey’s post hoc test revealed differences 
between senktide administered ICV and 
by LOx26 and all the other groups. 
Responsiveness of NAc shell DA 
to senktide delivered by liposomes 
conjugated to Lactoferrin
Figure 11 shows the central effect 
of senktide delivered by liposomes 
conjugated to Lactoferrin compared to S 
icv or loaded in stealth liposomes (SSL). 
Two-way ANOVA showed a significant 
effect of group [F(2,9)=18.23, p<0.001] 
and a significant group x time interaction 
[F(60,270)=2.06, p<0.0001]. Tuckey’s post hoc 
test revealed differences between senktide 
administered by SLLf and all the other 
groups.
 
Fig. 8. Gold modified Ox-26 liposomes: TEM 
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Senktide tissue distribution 
study  
Senktide distribution in 
brain tissue after different 
administration
Figure 12 shows the distribution of 
senktide in brain after the administration 
of S iv, loaded in stealth liposomes (SSL) 
or administered by SLOx26 or SLLf. One-
way ANOVA showed a significant effect of 
group [F(3,24)=60.93, p<0.0001]. Tuckey’s 
post hoc test revealed differences between 
SLOx26 and SLLf and all the other groups.
Senktide distribution in brain 
and liver 
Figure 13 shows the distribution of senktide 
in brain or liver tissue of rats. One-way 
ANOVA showed a significant effect of 
group [F(3,8)=2.23, p<0.0001]. Tuckey’s post 
hoc test revealed differences between liver 
and brain senktide distribution after the 
administration by SLOx26 and SSLf. Discussion
The main finding of this study is that 
senktide, delivered to the CNS by liposomes 
conjugated to the specific homing devices 
anti-transferrin-monoclonal antibody 
(SLOx26) and lactoferrin (SLLf ), are able 
to increase dopamine transmission in the 
NAc shell. This finding indicates that both 
SLOx26 and SLLf formulations represent 
an effective way to deliver senktide across 
the BBB. In general, the  value  of  brain 
uptake  of  a  drug  is equally  dependent 
on  two  factors:  the  drug  ability to 
permeate through the BBB and his plasma 
AUC. Senktide is a peptide with a high 
hydrophilicity that prevents its penetration 
through the BBB by passive diffusion. 
Moreover, BBB does not present specific 
carrier protein nor receptor able to transport 
senktide by CMT or RMT. These are the 
reasons why senktide cannot permeate 
the BBB to reach the brain parenchyma. 
However, senktide is able to increase NAc 
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shell if injected directly into the brain (icv) 
(Sandoval-Guzmán and Rance, 2004). 
In fact, senktide acts as the endogenous 
ligand neurokinin B (NKB) that stimulates 
DA neurons by high NK3 receptor 
occupancy at the VTA level. This results 
in an increased DA release at the level of 
DA terminal regions such as the NAc and 
a high level of DA D2 receptor occupancy 
post-synaptically (Spooren et al., 2005). 
For this reason, it has been hypothesized a 
clinical efficacy of NK3 receptor antagonists 
for psychoses or “hyper dopaminergic 
state”. NK3 receptor antagonists prevents 
NKB from binding to the NK3 receptor. 
Accordingly, the release of DA at the level 
of DA terminal regions (e.g. NAc) and 
post-synaptic D2 receptor occupancy is 
significantly reduced.  This study aimed to 
overcome BBB by different senktide loaded 
liposomes formulated using OX26 or Lf as 
homing devices. The ability of senktide to 
promote the DA release in the NAc shell 
when administered icv and the comparison 
of this effect with the administration 
of the free drug iv or loaded into stealth 
liposomes and SLOx26 and SLLf iv has 
been evaluated (figure 9-11). Interestingly, 
the iv administration of senktide loaded 
OX26 conjugated liposome exerted an 
increase of NAc shell dyalisate DA which 
overlapped the increase probuced by the 
icv administration of senktide (Fig 9) from 
20 to 180 min after the injection. This 
effect was mediated by NK3 receptor, in 
fact it was blocked by the administration 
of SB222200 30 min prior to the SLOx26 
administration (Fig 10).  Similar results 
were obtained by the administration of 
senktide loaded SLLf (Fig 11). However, 
the increase of DA was delayed (190-
300 min after injection) and this effect 
was probably mediated by a different 
kinectic of the Lf receptor compared to 
TfR. The increase of DA in the NAc shell 
is mediated by the action of senktide as 
agonist at VTA NK3 receptors. The results 
obtained show that the administration of 
SLOx26 encapsulated senktide produces a 
stimulation of DA transmission in the shell 
of the NAc comparable to that obtained by 
administration of senktide directly into the 
brain (icv). The fact that the increase of DA 
transmission in shell observed by us after 
administration of liposomes conjugated 
to OX26 is similar to that achieved by 
administration of S icv, shows, albeit in an 
indirect way, that the senktide has exceeded 
the BBB and for this it is able to exert its 
action in the CNS. The senktide produces 
a release of DA in the shell because it binds 
to NK3 receptors localized at the level of 
the VTA on mesolimbic dopaminergic 
neurons. Furthermore, the fact that 
the administration of NK3 antagonist 
(SB222200) completely abolishes the 
stimulation of DA transmission in 
shell produced by senktide, provides a 
confirmation of the central action of 
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senktide and of its effectiveness if properly 
formulated as in the case of SLOx26. The 
in vivo senktide up-take in brain and liver 
tissues was examined in rats 3 hours after 
administration (figure 12, 13). For the 
determination of the amount of senktide 
accumulated in tissues, the brain and the 
liver  were  post-mortem collected from 
treated animals and treated as previously 
reported. After administration of free 
peptide iv and peptide loaded stealth 
liposomes (SSL) iv, no measurable senktide 
was found in the brain (figure 12). As 
previously reported, the high hydrophilic 
nature of senktide and the absence of 
specific carrier protein nor receptor able to 
transport this peptide by CMT or RMT, 
prevent his accumulation in the brain 
parenchima. One of the characteristic of 
SSL is they ability to increase the circulation 
times  in  the bloodstream  increasing thus 
the plasma AUC, a prerequisite factor to 
enable a drug accumulation in the brain. 
However, as for free senktide, stealth 
liposomes cannot permeate through the 
BBB because a lack of specific transport 
mechanism and, as demonstrated in 
literature, their brain permeability-
surface area is 0 (Huwyler et al., 1997). 
After administration of SLOx26 and 
SLLf the amount of senktide found in 
the brain parenchima is 0.0110±0.0012 
and 0.0092±0.0005 µg per g of tissue, 
respectively. This corresponds of about the 
0,12% and 0.09% of the injected dose, a 
values similar to that reported in literature 
for small molecules delivered to the   brain 
using immunoliposomes.  The higher up-
take of senktide obtained 3 hours after the 
administration of SLOx26 is probably due 
to a different kinectic of the TfR receptor 
compared to LfR.  The senktide up-take 
in liver expressed as µg/g of tissue, was 
approximately 75 and  100-fold higher 
than in brain for SLOx26 and SLLf, 
respectively. TfR and LfR was identified 
in the brain microvessel but also in other 
tissues like monocytes, lymphocytes, 
liver, mammary epithelial cells, spleen, 
intestine etc (Chen et al., 2010). Many 
studies also showed that lactoferrin could 
bind to different receptors on hepatocytes 
including low-density lipoprotein 
receptor-related protein receptors, and the 
asialoglycoprotein receptors. Moreover, the 
high level of senktide found in liver can 
be explained considering the abundant 
expression of TfR and LfR on hepatocyte 
plasma membranes.  In particular the 
higher level of senktide found in liver after 
administration of SLLf could be the result 
of the high affinity of this tissue for Lf. 
Indeed, very rapid Lf clearance (93% of the 
dose) at 5 min after iv injection, was found 
to be mainly a result of association of 
lactoferrin to the liver, in particular to the 
parenchymal cells (Ziere et al., 1992). The 
liver uptake of OX26 is conversely, about 3 
times lower than measured for Lf (Ji et al., 
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S (0.1 mg/kg iv)
SSL (0.1 mg/kg iv)
SLOx26 (0.5 µ g/kg iv)
S (0.2 nmol/5 µ l icv)
SL (1 ml/kg iv)
LOx26 (1 ml/kg iv)
Fig. 9. Responsiveness of  NAc shell DA to senktide 
delivered by SLOx26
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2006). Moreover, although the presence 
of PEG on the surface of vesicles increases 
circulation times in the bloodstream 
delaying the opsonisation process and 
the liposomes up-take by macrophage 
cells in the liver and spleen (mononuclear 
phagocytic system or RES), however this 
process occur. As already mentioned, and 
according to our results, we can say that the 
formulations studied here are an effective 
method for the administration of peptide 
drugs for tachykinin receptor agonists 
or not. Further nanoformulations made 
for other animal species or humans, for 
example linked to a monoclonal antibody 
specific for the man (eg. HIR, monoclonal 
antibody to the insulin receptor) could 
represent a valid system for the delivery 
of molecules potentially useful in therapy, 
but until now not used because of their 
inability to cross the BBB.
In conclusion, the present observations 
indicate that both SLOx26 and SLLf 
formulations represent an effective way to 
deliver senktide across the BBB probably 
by a RMT (receptor mediated transport). 
According to their efficacy in term of 
effectiveness and rapidity of action, both 
formulations could be used for different 
therapeutic requirements.
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Nanosuspensions Introduction
The advent of combinatorial chemistry 
and high throughput screening in 
drug development programs has led to 
a generation of molecules with poor 
aqueous solubility and poor bioavailability 
profile. In recent years, the number of 
drug candidates defined as having low 
solubility has increased, and about 70% 
of this new drugs have shown poor 
aqueous solubility (Ku and Dulin, 2010). 
Moreover, approximately 40% of the 
marketed immediate release oral drugs are 
categorized as practically insoluble (<100 
µg/ml) (Takagi et al., 2006). Poor aqueous 
solubility is one of the major hurdles in the 
development of new compounds into oral 
dosage forms, since dissolution is the first 
step in the absorption of the drugs. The 
limited dissolution rate, in turn, frequently 
lead up to a low bioavailability of orally 
administered drugs, and compounds with 
aqueous solubility lower than 100 µg/
ml generally present dissolution-limited 
absorption (Hörter and Dressman, 
2001). Poorly soluble molecules 
have been successfully formulated by 
employing a variety of techniques such 
as: solubilization in surfactant solutions; 
use of cosolvents; pH adjusted solutions; 
emulsions; liposomes; complexation 
with cyclodextrins; and solid dispersions 
(Kesisoglou et al., 2007) (Patravale et al., 
2004). However, most of these techniques 
require a large amount of additives limiting 
their use from the safety perspective. 
Moreover, when drugs are insoluble in 
both aqueous and organic media (the so-
called ‘brick dust drugs’), these approaches 
are almost ineffective. For all these reasons, 
in the last decades, drug nanocrystal 
technology has been strongly studied and 
developed and without doubt, it represents 
one of the highlights in pharmaceutical 
field. This technology, in general, allow to 
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generate nanosuspensions, a dispersions of 
drug crystals in a liquid medium (typically 
water), with size below 1µm, stabilized by 
surfactants or polymers (Fig. 1). 
Nanosuspensions provide an alternative 
method to formulate poorly soluble 
compounds and their pharmaceutical 
benefits include improvement in 
formulation performance, such as 
enhanced dissolution velocity and 
saturation solubility, reproducibility of oral 
absorption, improved dose-bioavailability, 
proportionality and increased patient 
compliance via reduction of number 
of oral units to be taken (Müller et al., 
2001) (Rabinow, 2005). In particular, 
nanocrystal serves as ideal delivery system 
for oral drugs having the dissolution 
velocity as rate limiting step for absorption. 
In addition, nanocrystals can be injected 
intravenously as aqueous nanosuspensions 
(Rabinow et al., 2007) and also employed 
in ocular (Pignatello et al., 2002) and 
pulmonary delivery (Jacobs and Müller, 
2002). Another remarkable aspect is 
how fast these nanocrystals entered the 
pharmaceutical market. It took about 
25 years for the liposomes to appear in 
pharmaceutical products on the market 
(around 1990, e.g. Alveofact from Dr. 
Thomae GmbH). It was less than 10 years 
for the nanocrystals, having the first patent 
applications filed at the beginning of the 
1990s (Keck and Müller, 2006), and the 
first product Emend® on the market in 2000. 
All these advantages have so tremendous 
impacts on promoting drug nanocrystals 
successfully from experimental researches 
to patients that several products have been 
launched into market (Table 1). 
Preparation methods
Now a day exists basically two main approaches 
to produce drug nanosuspensions: the so called 
‘bottom up’ and ‘top down’ (Fig. 2).
Top-down processes consist of particle size 
reduction of large drug particles into smaller 
particles using various wet milling techniques 
such as media milling, microfluidization and 
high pressure homogenization. No harsh 
solvents are used in top down techniques; 
moreover, this technology can be employed 
for all insoluble drugs including “brick dust 
drugs”.
The bottom-up process is broadly called a 
precipitation process, because the principle 
here is to precipitate drug particles from a 
supersaturated solution of the drug in the 
presence of a stabilizer. Various adaptations 
of this approach include: solvent–anti-solvent 
method; supercritical fluid processes; spray 
drying and emulsion–solvent evaporation 
(Date and Patravale, 2004) (Rabinow, 
 
Fig. 1. Schematic representation from micro to 
nano size
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Product/Company  Drug compound  Nano -sizing 
approach  
Administration 
route
Date of FDA 
approval
Rapamune®/Wyeth  Sirolimus  Top – down  
media milling  
Oral  2000  
Emend®/Merck  Aprepitant  Top – down  
media milling  
Oral  2003  
Tricor®/Abbott  Fenobrate  Top – down  
media milling  
Oral  2004  
Megace® ES/Par 
Pharma  
Megestrol acetate  Top – down  
media milling  
Oral  2005  
Tridlide™/Skye 
Pharma  
Fenobrate  Top – down  
HPH  
Oral  2005  
Invega 
Sustenna/Johnson  
& Johnson  
Paliperidone 
palmitate  
Top – down  
Media milling  
Injection  2009  
 
 
  
  
Table 1. Key characteristics of available 
commercial drug products based on drug 
nanoparticle technology
Attrition - 
for example, 
milling
Agglomeration
Dissolution
Nucleating and 
crystal growth
Water molecule Water - surfactant interaction
ba
Fig. 2. Nanosuspension preparation techniques
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2004). Top down technologies
Media milling
Wet ball milling WBM (also referred as 
pearl milling or bead milling) is by far the 
most frequently used production method 
for drug nanocrystals in the pharmaceutical 
industry. Around the 1990s Gary Liversidge 
and his colleagues from Sterling Drug Inc./
Eastman Kodak have applied a wet media-
based milling technique, adapted from the 
paint and photographic industry, to reduce 
the particle size of poorly water-soluble 
drugs; (Liversidge and Conzentino, 
1995). 
This process has evolved since and 
eventually became well known as 
NanoCrystal® technology in the 
pharmaceutical industry and is to date 
the most successful nanosizing approach 
with currently 5 products on the market 
(Merisko-Liversidge and Liversidge, 
2011). 
The milling procedure itself is rather 
simple; therefore this process can be 
basically performed in almost every lab. 
The easiest way of doing WBM is through 
low energy ball milling (LE-WBM) using 
a jar filled with milling media (often just 
very simple glass beads.
This system is charged with coarse drug 
substance, preferably in micronized form, 
which is suspended in a dispersion medium 
(normally water or a buffer) containing at 
least one stabilizing agent. By moving the 
beads either with an electric stirrer (Fig. 
3A), a magnetic stirrer, or by moving the 
whole jar, with a roller plate or a mixer (Fig. 
3B), the milling beads can get in touch with 
drug particles. In the LE-WBM process, a 
combination of cleavage, abrasion and 
fractures due to the strong collisions 
between drug crystals and the beads can 
be assumed as the main mechanism of size 
reduction (Hennart et al., 2012). The 
process generally yields very fine particles 
with a narrow size distribution when it is 
Fig. 3A – 3B. Setup for low energy wet ball milling. 
(A) Vial filled with milling beads, suspension and 
a magnetic bar placed on a magnetic stirrer plate, 
the beads are moved by the rotating magnetic 
bar inside the vial. (B) Plastic bottle (small 
picture lower right) filled with milling beads and 
suspension moved by a standard mixer, the whole 
system is moved.
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performed long enough.
However, the relatively low energy input 
used in this techniques leads to very long 
milling times of several days (Liversidge 
and Conzentino, 1995) (Merisko-
Liversidge et al., 1996).
Alternative milling procedures based on 
high energy processes had to be developed 
in order  to make this process more desirable 
for industrial pharmaceutical applications. 
The NanoCrystalTM process in its current 
form is based on such a high energy wet 
ball milling process (HE-WBM) (Merisko-
Liversidge and Liversidge, 2008). A 
necessary prerequisite for HE-WBM is 
the availability of suitable equipment. The 
manufacturers for milling equipment had 
to develop equipment with sufficiently 
high power densities for the improved 
processes (Fig. 4).
Today, HE-WBM can be regarded 
as a standard procedure to produce 
nanosuspensions. Due to the much higher 
power density, the production times are 
significantly reduced. Normally, the drug 
needs to be exposed to the high energy for 
about 30–120 min in order to achieve a 
nanosuspension of good quality (Merisko-
Liversidge and Liversidge, 2011). In this 
case, the comminution is a result of shear 
stresses and compression forces inside the 
milling chamber (Kwade, 1999). As for 
LE-WBM, drug particles are reduced in 
size by abrasion and cleavage mechanisms 
(Hennart et al., 2012). It is obvious that 
high energy mills require special milling 
media which has to be properly selected 
based on the material of the inner surfaces 
of the mill, the agitator types and other 
factors. The use of glass beads or zirconium 
oxide milling beads can lead to significant 
contamination of the nanosuspension 
caused by the abrasion either of the milling 
beads or parts of the milling chamber 
(Hennart et al., 2010) (Juhnke et al., 
2012). Initially, impurities caused by 
abrasion were one of the major obstacles for 
a broader acceptance of WBM. Therefore, 
a major milestone for the broad acceptance 
of the milling process was the introduction 
of zirconium stabilized with yttrium 
beads or highly crosslinked polystyrene 
beads as milling media (Kesisoglou et 
al., 2007)  (Merisko-Liversidge et al., 
2003). This milling media shows elastic 
deformation, thereby the formation of 
cracks and abrasion from beads is reduced. 
This leads to product qualities which 
allow the use of nanosuspensions even 
for parenteral administration (Merisko-
Liversidge and Liversidge, 2011). In the 
early nineties, there was no equipment 
available to produce nanosuspensions at 
very small scale. Hence, it was difficult 
to use this formulation approach for 
discovery purposes. Today, even high-
energy mills are available for small-scale 
production of nanosuspensions. Several 
research groups have reported ways to use 
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Recirculation chamber
Coolant
Milling shaft
Milling media
Screen - retaining milling 
media chamber
Nanocrystals
Milling chamber
Motor
Charged with drug, 
water and stabilizer
Large drug 
crystals
Fig. 4. Schematic representation of the media 
milling process. The milling chamber charged 
with polymeric media is the active component of 
the mill. The mill can be operated in a batch or 
recirculation mode. A crude slurry consisting of 
drug, water and stabilizer is fed into the milling 
chamber and processed into a nanocrystalline 
dispersion. The typical residence time generated 
for a nanometer-sized dispersion with a mean 
diameter of <200nm is 30–120 min.
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existing planetary ball mills (Fig. 5A-5B) 
with modified sample holders which can be 
used to process several nanosuspensions at 
the same time (Juhnke et al., 2010) (Van 
Eerdenbrugh et al., 2009).  
With the commercial availability of suitable 
equipment for small-scale production up 
to the commercial scale production, wet 
ball milling can be regarded as scalable 
approach. This aspect has definitely 
helped for broader acceptance of this 
rather complex technology (Merisko-
Liversidge and Liversidge, 2011). The 
versatility of wet ball milling is certainly 
another, if not the most important aspect 
for the success of this technology. Almost 
any poor soluble drugs can be processed 
with wet media milling (Cooper, 2010). 
Interestingly, most particle sizes reported 
for nanosuspensions prepared by wet ball 
milling are in the range between 100 and 
300 nm, irrespectively whether LE-WBM 
or HE-WBM was used. All these aspects 
have opened the possibility to use wet 
ball milling as a platform technology for 
formulating poorly soluble compounds. 
High pressure homogenization 
(HPH)
The application of HPH as particle size 
reduction method requires the availability 
of special equipment and it cannot be 
tested with a system as simple as “beads 
in a beaker”. The use of homogenizers was 
already described for the production of 
liposomes and emulsion systems (Brandl 
et al., 1990) (Collins-Gold et al., 1990), 
moreover, high pressure homogenizers can 
also be used for the production of solid 
lipid nanoparticles or nanostructured lipid 
carriers (Müller et al., 2000) (Müller 
et al., 2002) (Müller et al., 2011). The 
possibility to employ the production 
equipment for various formulation 
approaches (multi-purpose production 
lines) is an important advantage, as it 
is rather costly to establish production 
lines in-house. In this technology we 
can recognize three basic processes used: 
Microfluidizer technology (IDD-PTM 
technology) based on the jet stream 
principle; piston-gap homogenization 
either in water (Dissocubes® technology, 
SkyePharma) or alternatively in water-
reduced/non-aqueous media (Nanopure® 
technology, prev. PharmaSol GmbH, 
Berlin, now Abbott Laboratories). The 
Microfluidizer technology (Fig. 6) is 
based on the jet stream principle and 
can generate small particles by a frontal 
collision of two fluid streams in a Y-type 
or Z-type chamber under pressures up to 
1700 bar. The jet streams lead to particle 
collision, shear forces and cavitation forces 
(Microfluidizer®, Microfluidics Inc.). Often 
a relatively high number of cycles (50–100 
passes) are necessary to obtain sufficient 
particle size reduction. SkyePharma 
Canada Inc. (formerly Canadian company 
Fig. 5A. Planetary ball mill
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Material and balls fall back down
Lifting plates carrying the material up the 
side of the SAG mill
Direction of rotation of mill
Fig.  5B. Schematic representation of the inside of 
an agate jar in a planetary ball mill
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Research Triangle pharmaceuticals (RTP)) 
uses this principle for their Insoluble Drug 
Delivery-Particles (IDD-PTM) technology 
to achieve the production of submicron 
particles of poorly soluble drugs (Keck and 
Müller, 2006). 
The Dissocubes® technology was developed 
by Müller and co-workers by employing 
piston-gap homogenizers (e.g. APV 
Gaulin/Rannie homogenizers) (Fig. 7). The 
technology was acquired by SkyePharma 
PLC in 1999. This approach consists in 
forcing a drug dispersed in an aqueous 
surfactant solution (macrosuspension) by 
a piston under pressure (up to 4000 bar, 
typically 1500–2000 bar) through a tiny 
gap (5–20 µm). Previously, this coarse 
suspension is pre-milled passing several 
times through the HPH at low pressure 
(about 500 bar). Later, the applied pressure 
is increased step-wise from 10% to 100% 
in order to avoid clogging of the narrow 
homogenization gap. This explains the 
importance of the pre-mixing procedure 
for deagglomeration and wetting purposes, 
especially when relatively coarse material 
is processed. The resulting high streaming 
velocity of the suspension causes an 
increase in the dynamic pressure. This is 
compensated by a reduction in the static 
pressure below the vapor pressure of the 
aqueous phase; hence, water starts boiling 
forming gas bubbles. These gas bubbles 
collapse immediately when the liquid leaves 
the homogenization gap (=cavitation). The 
drug particles are reduced in size due the 
high power of the shockwaves caused by 
cavitation together with shear forces and 
collision.
Another approach using the piston-gap 
homogenizer is the Nanopure® technology. 
This technology uses a primary dispersion 
medium, non-aqueous liquids, oils, liquid 
and solid (melted) PEG, or water reduced 
media (e.g. glycerol–water, ethanol–water 
mixtures), and optionally homogenization 
at low temperatures. In general, several 
homogenization cycles are needed to reach 
the minimal particle size. The number of 
passes (homogenization cycles) depends 
on many factors. Thereby, the employed 
drug delivery technology defines the type 
of homogenizer as well as the process 
conditions (e.g. IDD-PTM technology, 
Dissocubes® or the Nanopure® technology) 
(Keck and Müller, 2006) (Shegokar 
and Müller, 2010). Additional factors 
determining the process efficiency include 
size of the starting material, hardness 
and amount of the drug and maximum 
pressure that can be reached by the 
machine. In general, higher pressure leads 
to faster particle size reduction (Dumay et 
al., 2013) (Kluge et al., 2012). The size of 
the impaction zone and the corresponding 
volume are important factors, as they 
determine proportionally the power 
density of the equipment. HPH is less 
prone in generating process impurities 
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Ending particles
ending size: 74 microns
Starting particles
starting size: 500 microns
Outlet reservoir
cooling jacket
Intensier pump 
constant pressure
Inlet reservoir Fixed geometry
patented interaction
chamber
Pressure gauge
Pressure to 40,000 psi
Fig. 6. Microfluidizer technology
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as consequence of abrasion and wearing 
of the equipment compared to WBM. 
Although high pressure homogenizers 
consist mainly of steel parts, the impurity 
levels found in nanosuspensions prepared 
via HPH processes are considerably low. 
Abrasion and wearing of HPH equipment 
can occur when extremely hard material is 
processed in piston-gap homogenizers. 
HPH is a scalable process, which is 
applied not only in the pharmaceutical but 
also in the cosmetics and food industry 
(Dumay et al., 2013). Today high pressure 
homogenizers are available from ml-
scale to large production scale (Keck and 
Müller, 2006). There is no general rule, 
but it seems that HPH is the method of 
choice for relatively soft materials with 
tendency to smear when processed with 
others methods, such as WBM. Finally, 
HPH and WBM can be defined by far 
the most industrial relevant technologies 
to produce drug nanocrystals and it is 
represented by the six different commercial 
pharmaceutical products based on 
nanosizing approaches already approved. 
Bottom up technologies
Bottom-up processes have some advantages 
if compared with top-down technology. 
This advantages include that these are 
low energy processes, require simple 
instruments, are less expensive and can 
be operated at a low temperature, making 
them particularly suitable for thermolabile 
drugs (Rasenack et al., 2004). The particle 
size obtained by bottom-up technology 
has a narrow size distribution, unlike 
other top-down processes (Rasenack 
et al., 2004) (Zhang et al., 2008). The 
bottom-up process is broadly called a 
precipitation process, because the principle 
here is to precipitate drug particles from a 
supersaturated solution of the drug. The 
precipitation can be induced by processes 
that further increase the supersaturation 
in the system, such as evaporation of the 
solvent, reduction of temperature or by 
mixing it with an antisolvent. In the last 
20 years, a number of research studies have 
been published based on precipitation 
technology for preparation of nanoparticles 
of organic drug substances. Broadly, these 
studies can be classified in four categories: 
precipitation by liquid solvent–antisolvent 
addition, precipitation in presence of 
supercritical fluid, precipitation by removal 
of solvent and precipitation in presence of 
high energy processes. 
Precipitation by liquid solvent-
antisolvent method
Among the various precipitation 
techniques, nanoprecipitation by liquid 
solvent antisolvent addition has been the 
most reported. This is because of the fact 
that it is the simplest and the most cost 
effective method. List and Sucker in 1988 
first reported preparation of “Hydrosol” by 
Forcer
Homogenised
product
Homogenised
product
Seat
Gap ≈ 0.1mm
Fig. 7. Piston gap homogenizer
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controlled precipitation method (Gao et 
al., 2012). Later, Soliqs (Abbott GmbH 
& Co.KG, Ludwigshafen, Germany) 
developed the NanoMorph® technology for 
preparing nanosuspensions of amorphous 
form stable throughout the shelf life 
(Gao et al., 2012). Precipitation has been 
applied for years to prepare submicron 
particles within the last decade (Patravale 
et al., 2004). Typically, the drug is firstly 
dissolved in a solvent. Then this solution 
is mixed with a miscible antisolvent in the 
presence of surfactants. Rapid addition of 
a drug solution to the antisolvent (usually 
water) leads to sudden supersaturation of 
drug in the mixed solution, and generation 
of ultrafine crystalline or amorphous drug 
solids. This process involves two phases: 
nuclei formation and crystal growth. When 
preparing a stable suspension with the 
minimum particle size, a high nucleation 
rate but low growth rate is necessary. 
Both rates are dependent on temperature: 
the optimum temperature for nucleation 
might lie below that for crystal growth, 
which permits temperature optimization. 
The solvent for preparing the drug solution 
can be any organic solvent like acetone, 
ethanol, methanol, isopropanol (IPA), 
N-methylpyrrolidone (NMP), etc., a 
cosolvent or mixture of cosolvents like 
polyethylene glycols (PEGs), propylene 
glygol (PG), buffer system of particular 
pH (Dong et al., 2009) (Douroumis 
and Fahr, 2007) (Raghavan et al., 2003) 
(Wang et al., 2005). Often a solvent is 
selected which gives the highest solubility 
for the chosen compound, however, the 
interaction of stabilizer with solvent needs 
to be considered as well. The antisolvent 
used in this process is often an aqueous 
solution of some stabilizer (s). However, 
sometimes both the solvent and antisolvent 
can be organic solvent with sufficient 
miscibility (Zhang et al., 2006) (Zhu et 
al., 2010).
Mixing solvent and antisolvent is 
the simplest method for preparing 
nanoparticles. However, it has been 
observed that the addition of some 
external factors (such as ultrasonic wave) 
or undertaking the precipitation process in 
some altered environment (inside a freeze 
dryer, spray dryer or with high gravity 
reactive precipitation) often result in a 
smaller particle size or narrower particle 
size distribution (PSD). The lower particle 
size obtained by these modified methods 
is a result of either faster mixing to affect 
the nucleation stage or by arresting particle 
growth.
Sonoprecipitation
Ultrasonic sound has been used by various 
researchers to induce crystallization 
(Kumar et al., 2009) (Li et al., 2003) 
(Louhi-Kultanen et al., 2006) (Luque de 
Castro and Priego-Capote, 2007). The 
ultrasonic energy can be introduced simply 
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by dipping a probe sonicator in a vessel 
kept under stirring for mixing a solvent 
with an antisolvent (Dhumal et al., 2008). 
The ultrasonic source can also be fitted 
with a mixing device (Beck et al., 2010). 
Sonication increases micromixing, reduces 
particle growth and agglomeration, and it 
is possible to obtain spherical amorphous 
particle with uniform size distribution 
(Dhumal et al., 2008) (Xia et al., 2010). 
The particle size is dependent on sonication 
duration and intensity, horn length, depth 
of horn immersion and cavitation. As 
reported, it was possible to obtain a particle 
size as low as 80 nm (Dhumal et al., 2008) 
(Nishida, 2004) (Xia et al., 2010).
Evaporative precipitation 
techniques
Evaporative precipitation into aqueous 
solution (EPAS) is another modified 
solvent antisolvent precipitation method, 
which was first proposed by a research 
group at the University of Texas, Austin 
(Sarkari et al., 2002). In this process, the 
drug is dissolved in a low-boiling-point 
solvent and heated above its boiling point. 
Thereafter, the heated solution is sprayed 
into a heated aqueous medium with 
stabilizer.
EPAS was used for preparing nanocrystals 
of several active pharmaceutical ingredients 
(APIs). A relatively recent report has 
described a evaporative method for the 
preparation of nanosuspension (EPN) 
by simply mixing solvent/antisolvent, 
followed by quick evaporation of the 
solvent in rotary vacuum evaporator to 
obtain drug nanoparticles (Kakran et al., 
2010). 
Nanosuspension 
pharmacokinetic properties
It is well known that many characteristics of 
drug nanoparticle systems, such as particle 
size, surface properties and so on determine 
their release, absorption, distribution and 
targeting ability, which further influences 
the in vivo fates of nanoparticles (Müller 
and Wallis, 1993) (Brigger et al., 2002). 
Studies on drug nanocrystals have also 
disclosed the similar findings. 
Oral administration route
Drug absorption in the gasto intestinal tract 
(GIT) is considered to involve a dissolution 
step of the drug from formulation into 
aqueous luminal fluids followed by 
transporting the drug across the GI 
epithelium. The dissolution is considered 
as the rate determining process in the 
oral delivery (Dressman and Reppas, 
2000) (Wang and Thanou, 2010). Poorly 
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soluble compounds tend to be eliminated 
from the GIT before they completely 
dissolve. Biopharmaceutically acceptable 
formulations for poorly soluble drugs, 
mainly belong to the biopharmaceutics 
classification system (BCS) II and IV 
compounds (Fig. 8), are a challenge 
because slow and erratic dissolution 
prevent rapid and complete absorption 
of these compounds, especially for drugs 
mainly absorbed in a narrow window in 
the GIT. In general, drugs possessing a 
poor solubility exhibit simultaneously a 
very low dissolution velocity. For this class 
of drug, despite gut permeability and fast 
uptake of the drug from the gut lumen, 
the blood levels will be low because the 
drug does not dissolve sufficiently fast. At 
the same time, drug elimination from the 
blood takes place leading to this low drug 
levels. In addition, the low concentration 
gradient between lumen and blood leads to 
relatively slow drug diffusion from the gut 
to the blood.
Many reports suggest that drug nanocrystals 
have many positive effects on the oral 
drug delivery of poorly soluble drugs, 
generally, including increased maximum 
plasma concentration (Cmax), reduced 
time to maximum plasma concentration 
(Tmax), enhanced area under the blood 
concentration–time curve (AUC) and 
reduced fasted/fed variability.
The mechanisms responsible of the 
improved absorption could be majorly 
summarized as two points (Gao et al., 
2012):
1. improved solubility and 
dissolution rate
2. bioadhesion to the intestinal 
wall
In general, drugs possessing a poor 
solubility (saturation solubility, cs) exhibit 
simultaneously a very low dissolution 
velocity. The Noyes–Whitney law 
describing the dissolution velocity of a 
solid particle can explain this behavior.
dQ/dt: dissolution velocity
D: diffusion coefficient
A: drug powder surface area
Cs: drug concentration in diffusion layer or 
saturation solubility
C: drug concentration in surrounding 
liquid
h: diffusion layer
This equation describes the solid particle 
dissolution velocity dQ/dt which depends 
on the surface area A and on the ratio 
(cs – c)/h, where cs represents the drug 
concentration in diffusion layer, c is the 
bulk concentration of the drug in the 
surrounding liquid and h the diffusional 
distance above the drug particle surface. 
Micronisation is a very simple traditional 
approach to increase the dissolution 
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velocity by enlarging the drug surface 
area. The particle size of normally sized 
drug powders (approximately being in the 
range 20–100 µm) is reduced to a size in 
a range of approximately l–10 µm, the 
mean diameter being typically in the range 
somewhere between 2 and 5 µm. However, 
many new drugs coming from synthesis 
or biotechnological processes exhibit such 
a low solubility (and related dissolution 
velocity) that the increase in surface area, 
allowed by micronisation technique, is 
not large enough to achieve a sufficiently 
high dissolution velocity leading to 
therapeutic blood levels. Therefore, the 
next consequent step was taken, going 
from micronisation to nanonisation that 
means transferring the drug microparticles 
to drug nanoparticles. Drug nanoparticles 
possess sizes of approximately 10–1000 
nm, most production methods yield a main 
diameter somewhere between 200 and 400 
nm. Nanonisation has an additional effect 
compared to micronisation, it increases 
not only the surface area A, but also 
simultaneously the saturation solubility cs. 
The solubility of normally sized powders is 
a compound specific constant, depending 
only on the temperature and the solvent. 
This changes when one goes below a size 
of approximately 1 µm. The dissolution 
pressure increases due to the strong 
curvature of the particles leading to an 
increase in cs, the theoretical background 
being provided by the Ostwald–Freundlich 
equations (Brittain et al., 1991). 
According to Noyes–Whitney, this leads to 
a further increase in dQ/dt in addition to 
the gain by an increased surface area.
Moreover, according to the Prandl 
equation, the diffusion layer h is reduced 
for small particles (Muller et al., 1998) 
(Fig. 9).
The simultaneous increase in saturation 
solubility cs and decrease in h leads to an 
increased concentration gradient (cs – c)/h, 
thus enhancing the dissolution velocity in 
addition to the surface effect. 
Therefore, the drug nanocrystals are a smart 
delivery system, a universal principle, which 
can be applied to any drug because any 
drug can be diminuted to nanocrystals. The 
increase in the saturation solubility leads to 
the formation of a supersaturated solution 
compared to the solubility of normally 
sized drug powders (size »1µm). So, when 
drugs are administered as nanocrystal 
formulations, a high drug concentration 
gradient between GIT and blood vessel will 
markedly improve absorption and result in 
a high bioavailability (Fig. 10).
As said before, another important aspect 
is the mucoadhesion. It is generally 
known that nanoparticles possess general 
mucoadhesion to biological mucosa 
including GI mucosa (Ponchel et al., 
1997). This interaction also plays an 
important role in the enhancement of 
oral bioavailability. There are four general 
Fig. 9. Schematic representation of the diffusion 
layer of solid particles of different diameter in a 
dissolution process
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Fig. 10. Differences in diffusion and absorption by 
both micro and nano particles
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theories of mucoadhesion mechanisms 
of nanocrystals or more in general of 
nanoparticles: the electronic theory 
(electrostatic attraction forces between 
the surfaces of particles and mucus), the 
adsorption theory (secondary forces such as 
hydrogen and van der Waals bonds between 
the surfaces of particles and mucus), the 
diffusion theory (interpenetration and 
physical entanglement of the protein of 
the mucus and polymer chains) and the 
trapping theory (retention of nanoparticles 
by the uneven mucosa surface). Because of 
mucoadhesion to GI mucosa, drugs can be 
released exactly at the absorption sites. This 
leads to a higher concentration gradient 
and also a prolonged retention time (Li et 
al., 2009).
Poorly soluble drugs often exhibit 
increased or accelerated absorption when 
they are administered with food. This can 
be attributed to the enhancement of the 
dissolution rate in the GIT caused by many 
factors such as delayed gastric emptying, 
increased bile secretion, larger volume of 
the gastric fluid, increased gastric pH (for 
acidic drugs), and increased splanchnic 
blood flow (Jinno et al., 2006). In general, 
the fasted/fed variation will be dangerous 
for drugs with a narrow therapeutic window. 
When poorly soluble drugs are formulated 
as uniform nanosuspensions, this variation 
may be minimized. The reason is that 
the dissolution rate of nanocrystals is fast 
enough even under the fasted condition. 
Then, the absorptions both in fasted and 
fed state might be a permeability-limited 
progress, and the absorption difference 
resulting from variable dissolution between 
the two conditions will be eliminated.
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Introduction
Among the multiple, complex functions 
of mammalian skin, the most important 
is to form an effective barrier between 
the ‘inside’ and the ‘outside’ of the 
organism (Fig. 1). The skin has evolved 
defensive mechanisms that give it physical, 
immunological, metabolic and UV-
protective barriers to allow it to inhibit 
attacks by microbes, toxic chemicals, UV 
radiation and particulate matter (including 
nanoparticles, which may occur in the 
natural environment). 
Skin consists of two main layers (Fig. 2). 
The underlying dermis contains a variety 
of cell types, nerves, blood vessels and 
lymphatics embedded in a dense network 
of connective tissue. Above the dermis 
and separated from it by the basement 
membrane, the epidermis is composed 
mostly of layers of stratified keratinocytes, 
where the SC cells or corneocytes are 
bathed in a protein-rich envelope with 
an outer lipid envelope, surrounded by 
an extracellular lipid matrix. Interspersed 
amongst the keratinocytes in the viable 
epidermis are cells with roles such as 
melanin production (melanocytes), 
sensory perception (Merkel cells) and 
immunological function (Langerhans and 
other cells). In addition to the structured 
cellular components of skin, there are 
appendages including the pilosebaceous 
units (hair follicles and associated sebaceous 
glands), apocrine and eccrine sweat glands. 
In particular, the SC represents the 
principal barrier against the percutaneous 
penetration of chemicals and microbes 
and is capable of withstanding 
mechanical forces. It is further involved 
in the regulation of water release from the 
organism and into the atmosphere, known 
as transepidermal water loss (TEWL). The 
SC forms a continuous sheet of protein-
enriched cells (corneocytes) connected 
Nanosuspension 
improves tretinoin 
photostability and 
delivery to the skin
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Sweat gland pore
Basement membrane
Sweat gland duct
Touch receptor
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Subcutaneous layer
Dermis
Epidermis
Hair shaft
Fig. 2. Skin structure
Barrier to water loss Stratum corneum
Epidermis
Prevention of excessive water loss and dessication; disrupted barrier leads to 
increased transepidermal water loss
Physical assaults
(mechanical injury, UV-irradiation)
Microbial assaults
(bacteria, fungus, virus)
Chemical assaults
(irritants, allergens)
Fig. 1. Functions of the epidermal ‘inside-outside’ 
and ‘outsideinside’ barrier.
66
by corneo desmosomes and embedded in 
an intercellular matrix enriched in non-
polar lipids and organized as lamellar 
lipid layers. In particular, corneocytes 
originate from keratinocytes after a 
process of keratinisation, in which the 
cell differentiates and moves upward from 
the basal layer (stratum basale), through 
the stratum spinosum and stratum 
granulosum, arriving finally to stratum 
corneum. On reaching the SC, cells become 
anucleated and flattened and are eventually 
sloughed off (Bouwstra and Honeywell-
Nguyen, 2002).  Although the SC is 
recognized as the most important physical 
barrier, the nucleated epidermal layers are 
also significant in barrier function. A low 
to moderate increase in TEWL occurs 
after removal of the SC by tape-stripping, 
whereas loss of the entire epidermis leads 
to a severe disturbance in barrier function. 
Loss of the SC and parts of the granular 
layers in staphylococcal scalded skin 
syndrome are not life-threatening (Elias 
et al., 1977). In contrast, suprabasal 
and subepidermal blistering diseases like 
pemphigus vulgaris, toxic epidermal 
necrolysis (Lyell syndrome) and severe 
burns (intra as well as subepidermal 
blistering) are lifethreatening when large 
areas of the body are involved.
Tretinoin (TRA) (Fig. 3) is the all-
trans-retinoic acid form of vitamin A, 
commonly commercially formulated in 
cream and gel forms for the treatment of 
acne vulgaris, due to its ability to regulate 
epithelial cell growth and differentiation, 
sebum production and collagen synthesis 
(Zouboulis, n.d.).
Topical TRA is also used to reduce rhytids 
and photoaging (Darlenski et al., 2010). 
However, as all topical retinoids, TRA may 
cause xerosis, irritation, erythema, and 
desquamation due to hyperproliferative 
effect and increased cell turnover of the 
epidermal keratinocytes. Moreover, its 
topical use is limited by its poor water 
solubility and photolability (Manconi, 
2003) (Ourique et al., 2011). Indeed, 
TRA is known to be susceptible to 
degradation by light, heat, and oxidizing 
agents and, under light exposure, it is 
rapidly isomerized, forming 13-cis and 9- 
cis retinoic acids (Brisaert and Plaizier-
Vercammen, 2000) (Manconi, 2003). 
In order to overcome all these drawbacks, 
nanoparticulate drug delivery systems, 
which include liposomes, niosomes, 
nanocapsules, solid lipid nanoparticles, 
and nanoemulsions, have been used widely 
(Manconi, 2003) (Sinico et al., 2005) 
(Manconi et al., 2006) (Shah et al., 
2007) (Ourique et al., 2011). Among 
these approaches, vesicular carriers have 
been investigated to the main extent 
and incorporation of TRA in vesicular 
formulations has been largely studied to 
circumvent the undesirable effects of the 
drug, to maximize its accumulation into 
Fig. 3. Trans retinoic acid structure
H3C CH3
CH3
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O
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the skin, and to prevent its fast degradation. 
In particular, our group has demonstrated 
that different vesicular carriers (liposomes, 
niosomes, and penetration enhancer-
containing vesicles) are able to reduce TRA 
photodegradation (Manconi, 2003) as 
well as to strongly improve new born pig 
skin hydration and cutaneous retention of 
this drug (Sinico et al., 2005) (Manconi 
et al., 2006) (Manconi et al., 2011). 
However, crucial factors that need to be 
considered for topical formulation and 
design of nanomedicines also include drug 
loading, stability, reproducibility, and 
cost of manufacturing. Nanosuspensions, 
sub-micron colloidal dispersions of drug 
particles stabilized by surfactants, polymers 
or a mixture of both, have high drug 
loading, low incidence of side effects due 
to excipients, high reproducibility, and 
low cost  (Patravale et al., 2004). Owing 
to the increased surface-to-volume ratio 
of the nanocrystals, especially for particle 
size below 1 µm, an increase in saturation 
solubility and very fast dissolution rate 
can be obtained (Müller and Peters, 
1998). Therefore, the aims of this work 
were to improve cutaneous targeting 
and photostability of tretinoin by using 
nanosuspension formulation of TRA 
(nanoS). To this purpose, the TRA skin 
permeation and deposition were studied in 
vitro by diffusion experiments through new 
born pig skin while TRA photostability 
was investigated by irradiating samples 
with UV light, set at 366 nm. As an 
appropriate comparison, an O/W 
nanoemulsion (nanoE) was also prepared 
and tested. Indeed, nanoemulsions 
have shown to be promising drug 
delivery systems with practical role for 
pharmaceutical, cosmetic, and chemical 
industry applications. Moreover, they 
have shown to be particularly useful 
as vehicle for dermal and transdermal 
delivery especially of hydrophobic 
compounds (Shakeel et al., 2012) (Wu 
et al., 2013). NanoS was prepared using 
precipitation method, meanwhile TRA 
nanoE was obtained by sonication. 
Formulations were characterized by photo 
correlation spectroscopy for mean size 
and size distribution, DSC for studying 
TRA cristallinity and melting point, and 
by transmission electron microscopy 
for morphological studies. Dermal and 
transdermal delivery of both TRA systems 
were tested in vitro by using Franz 
diffusion cells, working in nonocclusive 
conditions. At the end of the experiments, 
TRA amount delivered into/through the 
skin was detected by a HPLC method. 
The drug photostability was investigated 
also in comparison with a TRA methanolic 
solution, used as a further control.
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Materials and Methods
Materials
Soybean lecithin was obtained from 
Galeno (Italy). Glycerol, trans-retinoic acid 
(TRA), isopropyl myristate, and all the 
other products were of analytical grade and 
were purchased from Aldrich, Milan, Italy.
Nanoemulsion preparation
Composition of nanoE is shown in Table 
1. The nanoE was prepared as previously 
reported (Lai et al., 2008). Briefly, soybean 
lecithin, TRA, and isopropyl myristate 
were blended under constant stirring. Then 
the water phase (water and glycerol) was 
added and the mixture homogenized for 5 
min using an Ultra Turrax T-25 basic (Ika®-
Werke). At the end, the formed bi-phasic 
system was sonicated by a probe sonicator 
Soniprep (MSE, Crowley) for 60 cycles of 
10 s at constant amplitude. Nanoemulsion 
was prepared under yellow light and then 
stored in the dark at 4 ± 1 °C.
Nanosuspension preparation
Composition of nanoS is shown in 
Table 1. Nanosuspension was obtained 
in accordance with the precipitation 
method by liquid solvent–antisolvent 
addition (Sinha et al., 2013). TRA 
and soybean lecithin were dissolved in 
methanol. The organic phase was added 
dropwise into deionized water under 
magnetic stirring at room temperature. 
The organic solvent was removed at room 
temperature, under vacuum using a Buchi 
rotavapor R200 equipped with a vacuum 
pump membrane MZ-2c (Vacuubrand-
Wertheim, Germany). The absence of 
methanol residues was checked by HPLC. 
The final volume of the nanosuspension 
was adjusted to 20 ml with distilled water. 
Nanosuspension was prepared under 
yellow light and then stored in the dark at 
4 ± 1 °C.
Nanosuspension and 
nanoemulsion characterization
The average diameter and polydispersity 
index (P.I.) of the samples were 
determined by Photon Correlation 
Spectroscopy (PCS) using a Zetasizer 
nano-ZS (Malvern Instrument, UK). 
Samples were backscattered by a helium–
neon laser (633 nm) at an angle of 173° 
and a constant temperature of 25 °C. 
The instrument systematically and 
automatically adapts to the sample by 
adjusting the intensity of the laser and 
the attenuator of the photomultiplier, 
thus ensuring reproducibility of the 
experimental measurement conditions. 
The P.I. was used as a measure of the width 
of the size distribution: the less its value 
the more homogenous and monodisperse 
is the sample. Zeta potential was estimated 
using the Zetasizer nano-ZS by means 
of the M3-PALS (Phase Analysis Light 
Scattering) technique, which measures 
69
the particle electrophoretic mobility in 
a thermostated cell. All the samples were 
analyzed 24 h after their preparation. A 
long-term stability study of formulations 
stored at 4 ± 1 °C was performed by 
monitoring formulations average size, 
polydispersity, and surface charge over 90 
days. The DSC curves of TRA and TRA 
nanoS were recorded on a Perkin Elmer 
DSC 6 differential scanning calorimeter, 
calibrated with indium, at the heating 
rates of 10 °C/min. The thermal behavior 
was studied by heating 2 mg samples in 
aluminium crimped pans under nitrogen 
gas flow within the temperature range 
50–350 °C.
HPLC method
TRA content was quantified at 350 nm 
using a chromatograph Alliance 2690 
(Waters, Milan, Italy), equipped with a 
photodiode array detector and a computer 
integrating apparatus (Empower 3). The 
column was a Symmetry C18 (3.5 µm, 4.6 
mm × 100 mm, Waters), and the mobile 
phase was a mixture of acetonitrile, water, 
and acetic acid (84.5:15:0.5, v/v), eluted 
at a flow rate of 1.2 ml/min. A standard 
calibration curve was built up by using 
working, standard solutions. Calibration 
graphs were plotted according to the linear 
regression analysis, which gave a correlation 
coefficient value (R2) of 0.999.
Photodegradation study
The degradation study of tretinoin was 
carried in triplicate as previously reported 
(Manconi, 2003) by using a UV lamp set 
at 366 nm (Min UVIS, Desaga, GmbH, 
Germany). TRA methanolic solution, 
nanosuspension and nanoemulsion (2 ml in 
a glass flask) were exposed to UV radiation 
from a 30 W lamp (366 nm) for 1 h at a 
fixed distance of 10 cm. At regular time 
intervals (every 10 min), samples were first 
stirred and then 100 µl of the dispersion 
was withdrawn, diluted with methanol 
and finally analyzed by HPLC in order to 
quantify TRA concentration. Experiments 
were carried out at 25 ± 1 °C on samples 
with an initial TRA concentration of 350 
µg/ml.
In vitro skin penetration and 
permeation studies
Experiments were performed non-
occlusively using Franz diffusion vertical 
cells with an effective diffusion area of 
0.785 cm2, and new born pig skin. One 
day old Goland Pietrain hybrid pigs (~1.2 
kg) were provided by a local slaughterhouse. 
The skin, stored at −80 °C, was pre-
equilibrated in physiological solution 
(0.9%, w/v of NaCl) at 25 °C, 24 h before 
the experiments. Skin specimens (n = 12 
per formulation) were sandwiched securely 
between donor and receptor compartments 
of the Franz cells, with the stratum corneum 
(SC) side facing the donor compartment. 
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The receptor compartment was filled with 
5.5 ml with 5.5 ml of a hydroalcoholic 
solution (ethanol/PBS 50:50, v/v), which 
was continuously stirred with a small 
magnetic bar and thermostated at 37 °C 
throughout the experiments to reach the 
physiological skin temperature (i.e. 32 
°C). One hundred microliters of TRA 
nanosuspension or nanoemulsion were 
placed onto the skin surface. At regular 
intervals, up to 8 h, the receiving solution 
was withdrawn and replaced with an 
equivalent volume of pre-thermostated 
(37 °C) fresh hydroalcoholic solution, 
to ensure sink conditions. Withdrawn 
receiving solutions were analyzed by HPLC 
for drug content. After 8 h, the skin surface 
of specimens was gently washed (3 times) 
with 1 ml of distilled water, then dried 
with filter paper. The SC was removed 
by stripping with adhesive tape Tesa® 
AG (Hamburg, Germany). The method 
was previously validated by histological 
examination of stripped skin (Sinico et 
al., 2005). Each piece of the adhesive tape 
was firmly pressed on the skin surface and 
rapidly pulled off with one fluent stroke. 
Ten stripping procedures were performed 
consecutively. Epidermis was separated 
from dermis with a surgical sterile scalpel. 
Tape strips, epidermis, and dermis were cut 
and placed each in a flask with methanol 
and then sonicated for 4 min in an ice bath 
to extract the drug. The tapes and tissue 
suspension was centrifuged for 10 min at 
10,000 rpm, and the supernatant was then 
filtered and assayed for drug content by 
HPLC.
 Transmission electron microscopy 
(TEM)
Characterization of the external 
morphology of TRA nanosuspension 
was determined using transmission 
electron microscopy (TEM). A drop of 
nanosuspension and an equal volume of an 
aqueous 1% uranyl acetate solution were 
adsorbed on the surface of copper grid 
and dried at room temperature for 24 h. 
The sample was transferred into a TEM 
(Tecnai 12, FEI) operating at 120 kV. 2.9. 
Statistical analysis of data Data analysis 
was carried out with the software package 
R, version 2.10.1. Results are expressed as 
the mean ± standard deviation. Multiple 
comparisons of means (Tukey test) were 
used to substantiate statistical differences 
between groups, while Student’s t-test 
was applied for comparison between two 
samples. Significance was tested at the 0.05 
level of probability (p).
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Results and discussion
Composition of nanoemulsion (nanoE) 
and nanosuspension (nanoS) formulations 
are listed in Table 1, where the amount of 
the different compounds is expressed as 
% (w/w). As shown in the table, nanoE 
was prepared by using isopropyl mirystate 
as lipidic phase, and soybean lecithin as 
stabilizer. Both formulations, nanoE and 
nano S, were loaded with the same amount 
of TRA (0.035%, w/w) and stabilized 
with the same surfactant in different 
concentrations (1.2% and 0.0035%, 
respectively).
PCS diameter (Z-AVE), polydispersity 
index (PI), and Z potential of nanoE 
and nanoS were determined just after 
preparation and are reported in Table 2. 
Freshly prepared nanoE showed a Z-AVE 
of 175 nm (0.09 PI) and a Z potential of 
−69.7 mV, while freshly prepared nanoS 
presented a Z-AVE of 324 nm (0.24 PI) 
and a Z potential of −53.2 mV. As can 
be seen, both formulations, nanoE and 
nanoS, showed very highly negative zeta 
potential values that should ensure high 
stability against aggregation phenomena. 
Stability was checked by measuring 
average diameter, polydispersity index 
and Z potential of formulations stored 
at 4 ± 1 °C for 90 days. As shown by the 
Table 2, freshly prepared nanoE was nicely 
homogeneously dispersed with reduced 
particle size and PI, in comparison with the 
nanoS that was slightly less homogeneously 
disperse. However, Table 2 clearly shows 
that nanoemulsion (nanoE) was less stable 
than the nanoS. Indeed, after only one 
day on storage, the average diameter of 
nanoE increased from 175 nm to 344 nm, 
reaching a mean size of 745 nm after 90 
days. The low stability of this formulation 
was also confirmed by the increasing of 
polydispersity index value from 0.09 to 
0.69. By contrast, nanoS maintained 
similar mean diameter and polydispersity 
index values during all the checked period 
(~330 nm and 0.25 PI). Nanosuspension 
data were confirmed by TEM images (Fig. 
4).
To evaluate the influence of the preparation 
method on the TRA degree of cristallinity 
and melting point, DSC characterization 
of nanoS was also performed. As reported 
in literature (Caviglioli et al., 2006), 
two polymorphic forms of TRA are 
known: form I and form II. The thermal 
behaviour of form I shows an endothermic 
peak at 153.39 °C, due to the solid 
state transition from the monoclinic to 
the triclinic structure, which melts at 
184.58 °C; while form II shows only 
the endothermic peak at 183.7 °C. The 
commercial trans-retinoic acid used in this 
study to produce nanocrystals agrees with 
form I. The thermic profile comparison 
between commercial and nanoS TRA 
evidenced that nanosuspension process 
 
  
  
Formulations  
 Compounds % (w/w)  NE  NS  
TRA  0,035  0,035  
Isoprpyl myristate  10  -  
Glycerol  2,26  -  
Soybean lecithin  1,2  0,0035  
Water  86,5  99,9  
Table 1. Sample composition
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produced trans-retinoic acid form II. Since 
the two polymorphs show comparable 
solubility values, the solid state transition 
that occurred during nanosuspension 
preparation did not affect drug behaviour, 
which was mainly influenced by the 
reduced particle size (Caviglioli et al., 
2006). The low stability of the nanoE could 
be the consequence of the choice of the 
stabilizer, the soybean lecithin, which was 
used here to have nanoS and nanoE with 
the same additive. Indeed, while the small 
amount of this phospholipid mixture was 
capable of highly stabilizing the nanoS, the 
nanoE showed aggregation phenomena on 
storage. Before testing nanoS for the (trans)
dermal delivery of TRA, we evaluated 
the influence of the nanosuspension on 
TRA photostability, which was studied 
by irradiating TRA nanoS with UV light 
(λ=366 nm) in comparison with nanoE 
a TRA methanolic solution (controls). 
HPLC analyses showed that TRA 
photodegradation in methanol is very fast 
and, after only 10 min of UV exposure, 
a great amount of drug was degraded. 
Actually, after 1 h of UV irradiation, only 
approximately 27% of the initial TRA 
concentration was still present. On the 
contrary, when nanosuspension (nanoS) 
and nanoemulsion (nanoE) were tested for 
the same period of time, the 83% and 52% 
of the initial drug concentration was found 
to be stable. Fig. 5 clearly shows that a good 
linear correlation was obtained by plotting 
tretinoin concentration as a function of 
time during the 1 hour irradiation with 
UV light of the methanolic solution (R2 
= 0.954). The same linearity was obtained 
studying the photodegradation of the drug 
in nanoS and nanoE (R2 = 0.925 and R2 
= 0.953 respectively). Therefore, as shown 
previously, the photodegradation of TRA 
can be treated as a zero order kinetic in 
all the studied samples (Manconi, 2003). 
Photodegradation rate constants (k) and 
half-lives (t1/2) of TRA in the different 
formulations exposed to UV light for 1 h 
are shown in Table 3. TRA in methanol 
solution showed a half-life time of about 0.4 
h that became more than two fold higher 
in nanoE (t1/2 = 0.9 h), and, surprisingly, 
even 7.5-fold higher with nanoS (t1/2 = 3 
h). Therefore, nanosuspensions were able to 
significantly improve TRA photostability 
in comparison with nanoE and methanol 
solution. This behaviour can be explained 
as a consequence of the TRA nanocrystal 
structure. In fact, here, only the external 
TRA molecules of the nanocrystals can be 
irradiated and, therefore, degraded (Del 
Rosso et al., 2012). On the contrary, in 
both nanoE and methanolic solution, 
TRA is molecularly disperse in a solvent 
(isopropylmiristate and methanol, 
respectively) and, therefore, more exposed 
to the UV rays that can reach and degrade 
TRA molecules more easily. Moreover, it 
is well known that reactions at molecular 
 
  
  
nano E nano S 
MD (nm) PI ZP (mV) MD (nm) PI ZP (mV)
D0 175 ± 2,1 0,09 ± 0,01 - 69,7 ± 1,3 324 ± 1,5 0,24 ± 0,01 - 53,2 ± 1,0
D1 344 ± 16 0,38 ± 2,1 - 76,6 ± 0,3 307 ± 1,8 0,17 ± 0,01 - 57,4 ± 0,5
D7 427 ± 28 0,42 ± 0,02 - 57,6 ± 0,5 329 ± 11 0,28 ± 0,01 - 48,4 ± 0,3
D14 460 ± 6,1 0,45 ± 0,01 - 62,2 ± 0,7 343 ± 7,6 0,28 ± 0,01 - 46,4 ± 0,9
D30 545 ± 33 0,58 ± 0,1 - 60,9 ± 0,5 322 ± 5,1 0,26 ± 0,02 - 47,8 ± 1,9
D60 1060  ± 33 0,84 ± 0,02 - 55,7 ± 0,2 316 ± 3,2 0,22 ± 0,04 - 47,7 ± 0,3
D90 745 ± 82 0,69 ± 0,08 - 59,9 ± 1,1 330 ± 8,5 0,27 ± 0,01 - 49,3 ± 1,2
Table 2. Mean size (Z-AVE), polydispersity index 
(PI) and Z potential (ZP) of TRA nanoemulsion 
and nanosuspension monitored during a 90-day 
period on storage at 4 ± 1 °C
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level are faster and easier in solution. The 
slower photodegradation rate of TRA in 
nanoE, when compared to the methanol 
solution, can be ascribed to the protection 
of the lecithin layer around the oil droplets. 
TRA delivery into and through newborn 
pig skin was evaluated in vitro under 
non occlusive conditions, using Franz 
vertical diffusion cells. During this study, 
percutaneous delivery of TRA from nanoS 
was compared to that from nanoE, used 
as control. Comparison of data obtained 
from nanoS and nanoE (Fig. 6) highlights 
a different TRA delivery into and through 
the pig skin with the two formulations. 
As expected, the nanoE led to a higher 
drug deposition and transdermal delivery 
than nanoS. However, differences of 
drug deposition in the three main skin 
strata (SC, epidermis and dermis) were 
not statistically significant (p > 0.05) 
while a strong and statistically significant 
difference was detected in the amount of 
permeated drug: nanoE led to a mean value 
of ≈6.5% of the applied drug delivered to 
the receiver, whereas using nanoS only a 
≈0.4% (p < 0.01) T of the applied TRA was 
found. Comparison of data obtained from 
nanoS and nanoE underlines the influence 
of the different formulations on the in 
vitro drug availability; nanoE is useful to 
improve both drug skin accumulation and 
transdermal delivery. On the contrary, 
nanoS is able to especially favour TRA 
accumulation into the skin and at the 
same time to reduce drug delivery to the 
systemic circulation. Indeed, using nanoS, 
TRA was mostly deposited in the stratum 
corneum (6.86 ± 1.10%) while a lower 
accumulation in the epidermis (3.09 ± 
0.81%) and a minimal deposition in dermis 
(1.65 ± 0.19%) and receptor fluid (0.28 
± 0.10%) were found. On the contrary, 
using nanoE, the highest drug delivery was 
found in in the stratum corneum (6.51 ± 
0.82%) and receptor fluid (6.64 ± 1.80%) 
and a smaller deposition in epidermis 
(4.34 ± 1.12%) and dermis (2.26 ± 
1.35%), respectively. Therefore, the results 
highlight the nanoS capability to favour 
TRA retention in the skin layers while 
minimizing transdermal delivery of the 
drug, responsible of its side effects. These 
results can be explained considering that 
poor solubility of solid crystals, like TRA, 
is generally linked to a slow dissolution 
rate. Thus, after permeation through a 
biological membrane of the few drug 
molecules in solution, further dissolution 
of the active crystals is not fast enough 
to replace the permeated molecules. As a 
result, the rate-limiting step for absorption 
of such drugs (so-called class II drugs of the 
biopharmaceutical classification system) is 
the dissolution rate (Desai et al., 1996) 
(Kasim et al., 2004) (Martinez and 
Amidon, 2002). In this case, in contrast, 
finely divided and uniformly suspended 
TRA nanocrystals possess an increased 
Fig. 4. TEM images of TRA nanosuspension 
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dissolution rate due to their large surface 
area and increased saturation solubility. 
Solid drug dissolves in the vehicle, diffuses 
through the vehicle to the skin, establishes 
local phase equilibrium with the outer 
layer of skin and finally, in the case of TRA, 
thanks to the larger concentration gradient 
penetrates the skin forming a depot in the 
lipophilic SC from which it diffuses. On 
the other hand, when a nanoemulsion 
is applied on the skin, two consecutive 
physical events may become rate-limiting 
steps in cutaneous permeation: the drug 
release from the vehicle and its penetration 
through the cutaneous barrier. These two 
processes are closely related, and both 
depend on the physicochemical properties 
of drug, vehicle, and barrier. 
As for nanoemulsion cutaneous behaviour, 
previous research indicated that the 
permeation process of lipophilic molecules 
was consistent with a skin-controlled 
mechanism (Fang et al., 2003). Differences 
between trend of release rates and fluxes can 
be attributed to the SC/vehicle partition 
coefficient. The degree of partitioning 
of the drug into the SC depends on 
relative affinity for the vehicle and for the 
intercellular environment. In this study, the 
higher drug permeability may be due to the 
soy lecithin (used in highly greater amount 
than in nanoS, Table 1) and the oily phase, 
which taken together act as penetration 
enhancers. Furthermore, as shown for 
microemulsions, the small particle size of 
the nanoE makes it an excellent carrier for 
promoting in vitro skin TRA permeation 
(Gupta et al., 2012). Overall results 
show that nanosuspensions are eligible 
for the use as suitable nanomedicine for 
dermal delivery of poorly soluble drugs 
such as tretinoin. Nanosuspensions are 
almost exclusively composed of the drug 
nanoparticles with small amounts of 
biocompatible and safe surfactants, such 
as the soy lecithin used in this work. This 
leads to a highly fast dissolution process 
that favours drug penetration into the skin. 
Moreover, although only few toxicological 
data are available at the moment, no 
side effects are known or expected from 
nanocrystal topically applied. Indeed, 
as suggested by (Müller et al., 2011), 
each solid macro/micro-particle applied 
on the skin will convert to nanocrystals 
during its dissolution process and, up to 
now, no intolerability has been reported 
(Müller et al., 2011). Therefore, the same 
should happen when nanocrystals are 
applied directly on the skin. Moreover, 
nanosuspensions show additional 
advantages over other colloidal carriers 
such as simple, reproducible, and scalable 
preparation methods.
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Fig. 5. Photodegradation of TRA in methanolic 
solution, nanoemulsion and nanosuspension after 
1 h of UV irradiation ( λ = 366 nm)
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Formulations  
 
Kinetic order  - K 0
a       t(1/2)
b
  (h)  
Methanolic  solution  First  72,83  0,4  
 
Nanoemulsion  
 
Zero  
 
48,31  
 
0,9  
 
Nanosuspension  
 
Zero  
 
16,46  
 
3  
Table 3. Photodegradation rate constants (K0) and 
half-lives (t1/2) of TRA methanolic solution, TRA 
nanoemulsion and TRA nanosuspension exposed to 
UV light for 1 h
Fig. 6. Cumulative amount of TRA retained into 
and permeated through pig skin layers (SC, stratum 
corneum; Ep, epidermis; D, dermis) after 8-h 
non-occlusive treatment with TRA nanoemulsion 
(nanoE) and nanosuspension (nanoS). Each value 
is the mean ± SD (n = 12)
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Conclusion
On the whole, this work has shown the 
high potentiality of nanosuspensions in 
dermal drug delivery of TRA. Indeed, 
nanoS has been demonstrated to be able to 
localize the drug into the pig skin in vitro 
with a very low transdermal drug delivery, 
which is responsible of systemic side 
effects of this drug. Moreover, the nanoS 
has shown to give comparable cutaneous 
TRA delivery as the nanoemulsion, 
which strongly enhanced in vitro 
transdermal drug delivery. Furthermore, 
the application of nanosuspension in 
topical TRA delivery has the advantage of 
increasing photostability of the drug also 
in comparison with the nanoemulsion. In 
conclusion, results of this work highlight 
that nanosuspension formulation approach 
could be a useful tool in the design of new 
TRA nanomedicines for treatment of skin 
diseases.
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Formulation 
strategy and 
evaluation of 
nanocrystal 
piroxicam orally 
disintegrating 
tablets 
manufacturing by 
freeze-drying
Introduction
For the past one decade, there has been 
an enhanced demand for more patient-
friendly and compliant dosage forms. 
As a result, the demand for developing 
new technologies has been increasing 
annually (Shyamala and Narmada, 
2002). Since the development cost of a 
new drug molecule is very high, efforts 
are now being made by pharmaceutical 
companies to focus on the development 
of new drug dosage forms for existing 
drugs with improved safety and efficacy 
together with reduced dosing frequency, 
and the production of more cost effective 
dosage forms. For most therapeutic agents 
used to produce systemic effects, the oral 
route still represents the preferred way 
of administration, owing to its several 
advantages and high patient compliance 
compared to many other routes (Valleri 
et al., 2004). Tablets and hard gelatin 
capsules constitute a major portion of 
drug delivery systems that are currently 
available. However, many patient groups 
such as the elderly, children, and patients 
who are mentally retarded, uncooperative, 
nauseated, or on reduced liquid-intake/diets 
have difficulties swallowing these dosage 
forms. Those who are traveling or have 
little access to water are similarly affected 
(Hanawa et al., 1995) (Mallet, 1996) 
(Porter, 2001). To fulfill these medical 
needs, pharmaceutical technologists have 
developed a novel oral dosage form known 
as Orally Disintegrating Tablets (ODTs) 
(Fig. 1).
US Food and Drug Administration 
Center for Drug Evaluation and Research 
(CDER) and Italian and European 
Pharmacopeia defines an ODT as “a 
solid dosage form containing medicinal 
substances, which disintegrates rapidly, 
usually within a matter of seconds, when 
placed upon the tongue” (Manach et al., 
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2004). The significance of these dosage 
forms is highlighted by the adoption of 
the term, “Orodispersible Tablet”, by the 
European Pharmacopoeia which describes 
it as a tablet that can be placed in oral 
cavity where it disperses rapidly before 
swallowing (“European Directorate for 
quality of Medicines,” 1998). The major 
claim of these formulations, compared 
with conventional oral forms, are 
increased bioavailability and faster onset of 
action. Dispersion in saliva in oral cavity 
causes pregastric absorption from some 
formulations in those cases where drug 
dissolves quickly. Buccal, pharyngeal and 
gastric regions are all areas of absorption 
for many drugs (Yarwood, 1990). Any 
pregastric absorption avoids first pass 
metabolism and can be a great advantage in 
drugs that undergo a great deal of hepatic 
metabolism. Furthermore, safety profiles 
may be improved for drugs that produce 
significant amounts of toxic metabolites 
mediated by first-pass liver metabolism and 
gastric metabolism, and for drugs that have 
a substantial fraction of absorption in the 
oral cavity and pregastric segments of GIT 
(Pfister and Ghosh, 2005). ODTs can be 
used easily in children who have lost their 
primary teeth but do not have full use of 
their permanent teeth (Mizumoto et al., 
2005). Recent market studies indicate that 
more than half of the patient population 
prefers ODTs to other dosage forms 
(Deepak, 2004) and most consumers 
would ask their doctors for ODTs (70%), 
purchase ODTs (70%), or prefer ODTs 
to regular tablets or liquids (>80%) 
(Brown, 2001). ODT products have 
been developed for numerous indications 
ranging from migraines (for which rapid 
onset of action is important) to mental 
illness (for which patient compliance is 
important for treating chronic indications 
such as depression and schizophrenia) 
(Ghosh et al., 2005). The performance 
of ODTs depends on the technology used 
during their manufacture. The necessary 
property of such tablets is the ability to 
disintegrate rapidly and disperse or dissolve 
in saliva, thereby obviating the need for 
water.
Various technologies have been developed 
to formulate ODT, the most known are: 
freeze drying, moulding, sublimation, 
spray drying, mass extrusion and finally 
direct compression. Independently of the 
technologies used for they production, 
an ideal ODT should meet the following 
criteria:
• does not require water for oral 
administration yet disintegrates and 
dissolves in oral cavity within a few seconds
• has sufficient strength to withstand the 
rigors of the manufacturing process and 
post-manufacturing handling
• allow high drug loading
• has a pleasant mouth feel
• is insensitive to environmental conditions 
	  
Fig. 1. Oral disintegrating tablet (ODT) 
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such as humidity and temperature
• is adaptable and amenable to existing 
processing and packaging machineries
• is cost-effective.
Piroxicam (PRX) (Fig. 2) is a non-steroidal 
anti-inflammatory drug characterized by 
slow absorption after oral administration 
because of its poorly water solubility 
(Amidon et al., 1995; Graf, 1985). 
Due to adverse side effects associated 
with its oral administration, such as 
gastric irritation, there is a considerable 
interest in developing new formulations 
to improve oral mucosa drug absorption. 
During the last years, our research group 
has been studying nanocrystals as tool to 
improve drug dissolution rate and, thus, 
bioavailability of poorly soluble drugs. In 
particular, it was demonstrated an improved 
dissolution rate for PRX nanosuspension 
incorporated in orally disintegrating 
tablets (ODT) in comparison with the 
corresponding coarse formulation (Lai et 
al., 2011).
In this work, we carried out a study on 
a new formulation strategy aimed to 
obtain nanocrystal Orally Disintegrating 
Tablets (ODT) of piroxicam with a drug 
dissolution profile faster than those of 
the ODTs currently available on the 
market. For this purpose, we focused 
our attention on the influence of ODT 
excipients, on the enhancement of the 
PRX dissolution rate and, therefore, on 
its direct absorption through the oral 
mucosa. The absorption in this site allows 
the drug to reach the systemic circulation 
bypassing the gastrointestinal tract, thus 
avoiding the first-pass metabolism of 
the liver. In particular, starting from the 
same PRX nanosuspension formulation, 
we prepared and studied ODT by using 
three different excipients: xanthan gum, 
gelatin, and crosscarmellose. Xanthan 
gum, a polysaccharide secreted by the 
bacterium Xanthomonas campestris and 
gelatin, a derived of collagen obtained 
from various animal by-products, are 
commonly used in food, pharmaceuticals, 
and cosmetic products as additive, gelling 
agent, rheology modifier, stabilizer, and 
binding agents. Croscarmellose sodium, 
or sodium CMC, is a cross-linked polymer 
of carboxymethylcellulose sodium. It is a 
white, fibrous, free-flowing powder, FDA-
approved disgregant, commonly used in 
pharmaceutical formulations to facilitate 
the breakup of a tablet in the gastro 
intestinal tract after oral administration. 
PRX nanocrystals were prepared using a 
high pressure homogenization technique 
(HPH) (Keck and Müller, 2006) and 
poloxamer 188 was used as a stabilizer. 
PRX nanosuspension ODT were 
prepared using a freeze-drying technology 
(Corveleyn and Remon, 1998; Owen 
et al., 2000; Sugimoto et al., 2006). 
Characterization of PRX nanocrystal 
ODT was carried out by different 
Fig. 2. Piroxicam structure
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techniques: infrared spectroscopy (FTIR), 
X-ray powder diffractometry (XRPD), 
differential scanning calorimetry (DSC), 
photon correlation spectroscopy (PCS). 
Dissolution study of PRX nanosuspension 
ODT was performed in distilled water 
(pH 5.5) and was compared to that of PRX 
coarse suspension ODT, PRX/poloxamer 
188 physical mixture, bulk PRX samples 
and a PRX commercial ODT (Feldene 
Fast®).
Materials and methods
Materials
Pluronic F68 (poloxamer 188) was a 
gift from BASF AG (Ludwigshafen, 
Germany). Maltodextrin (DE 39) having 
a Dextrose Equivalent (DE) equal to 39 
was kindly supplied by Roquette (France). 
Piroxicam (PRX), poly(ethylenglycol) 
4000 (PEG 4000), xanthan gum (XG) 
molecular weight approximately 3 x 105 
g/mol, gelatin, croscarmellose, citric 
acid, aspartame, mannitol and high-
performance liquid chromatography 
(HPLC)-grade methanol were purchased 
from Sigma–Aldrich (Milan, Italy). All the 
other compounds were of analytical grade 
and used as received from Sigma–Aldrich 
(Milan, Italy).
PRX polymorphic form 
preparation
All the crystalline forms of piroxicam were 
prepared following literature methods as 
previously reported (Vrečer et al., 1991; 
Vrečer et al., 2003). Commercial piroxicam 
agrees with form I (white prismatic 
crystals). Briefly, form II (white needle) was 
crystallised from commercial piroxicam 
hot saturated absolute ethanol solution. 
Form III (white powder) was obtained 
by spray drying. The monohydrate form 
(yellow powder) was obtained by dissolving 
commercial piroxicam in acetone and 
by slowly adding distilled water until the 
appearing of a yellow precipitate, which 
was filtrated and dried.
PRX polymorphic form solubility
The solubility of the different PRX 
polymorphic forms was determined in 
different media: pure water, water with 
different concentrations of poloxamer 
188, maltodextrin, PEG4000 and xanthan 
gum (or gelatin or croscarmellose) water 
solution at the same PRX/additives ratios 
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of the ODT formulation. PRX solubility 
was also determined in citric acid and/
or aspartame and/or mannitol water 
solutions. An excess of drug was added to 
the medium in screw capped tubes (10 ml) 
and stirred at 25 °C for 48 h. Each sample 
was centrifuged, then 0.2 ml of the clear 
supernatant was diluted with methanol 
and analysed by UV.
PRX/poloxamer 188 physical 
mixture preparation
Physical mixture was prepared by blending 
PRX and poloxamer 188 in an agata 
mortar until a homogeneous mixture was 
obtained, using the same drug/surfactant 
ratio (w/w) of corresponding ODT 
formulations (Table 1).
Coarse suspension preparation
Drug coarse suspensions were prepared 
dispersing PRX in a poloxamer 188 
bidistilled water solution using an Ultra 
Turrax T25 basic (IKA, Werke) for 1 min 
at 8000 rpm (Table 1).
Nanosuspension preparation
Nanosuspension was prepared using bulk 
PRX. PRX was dispersed in a poloxamer 
188 bidistilled water solution using an 
Ultra Turrax T25 basic for 1 min at 8000 
rpm. The obtained coarse suspension was 
sonicated for 1 h and then homogenised at 
high pressure (three cycles at 500 bar and 
30 cycles at 1500 bar) using an Emulsiflex 
C5 apparatus (Avestin, Ottawa, Canada). 
Nanosuspensions were prepared with 
the same drug/surfactant ratio (w/w) of 
corresponding ODT formulations (Table 
1).
ODT preparation
PEG4000, maltodextrins and Xanthan 
gum or gelatin or croscarmellose, were 
dissolved into the previously prepared 
nanosuspension or coarse suspension 
(Table 1). An amount of this suspension 
containing 20 mg of PRX placed in a 
PVC blister, was frozen at -20 °C and was 
freeze-dried overnight with an initial shelf 
temperature of -10 °C rising 20 °C at a 
pressure of 0.5 mbar using a freeze-dryer 
apparatus (Criotecnica, Rome, Italy).
Analytical characterization
FT-IR spectra were recorded using a Perkin 
Elmer (MA, USA) FT-IR Spectrometer 
“Spectrum One” in a spectral region 
between 4000 and 600 or 450 cm-1 for 
solid or liquid compounds, respectively, 
and analyzed by transmittance technique. 
Solid samples were mixed in a mortar with 
KBr (1:100) and pressed in a hydraulic 
press (14 tons) to small tablets, while 
one drop of liquid samples was placed 
between two windows of sodium chloride. 
The powder X-ray diffraction patterns 
were recorded with a Rigaku Miniflex 
diffractometer with a Ni-filtered CuKα 
Table  1. Composition of PRX ODT Formulations  
Components % (w/w)  ODT - Xanthan  
ODT -
Gelatin  
ODT -
Croscaramellose  
PRX  2.5  2.5  2.5  
Poloxamer 188  1.5  1.5  1.5  
PEG 4000  1  1  1  
DE 39  20  20  20  
Xanthan  2  -  -  
Gelatin  -  2  -  
Croscarmellose  -  -  2  
H2O  73.0  73.0  73.0  
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radiation detector (λ=1.5405 Å) operating 
at a voltage of 30 kV and a current of 15 
mA in the 2θ range from 3° to 60° with 
a scan angular speed of 2°/min and a scan 
step time of 2.00s. The DSC studies were 
carried out with a Perkin Elmer DSC 6 
differential scanning calorimeter calibrated 
with indium. Samples were scanned from 
50°-350°C at the heating rates of 10°C/
min in aluminium crimped pans under 
nitrogen gas flow. 
In vitro dissolution studies
In vitro dissolution studies were 
performed according to the United 
States Pharmacopeia (USP) by means 
of the rotating basket method (Erweka 
apparatus). The dissolution media was 
1000 ml of distilled water kept at 37 ± 
0.1 °C and at rotation speed of 100 ± 2 
rpm. At preselected time intervals, 1 ml 
sample was withdrawn (replaced with 1 
ml of pre-thermostated fresh dissolution 
medium), filtered through polycarbonate 
membranes (0.45 µm, Millipore), diluted 
with ethanol (1:5) and analysed by UV 
for PRX content. Dissolution tests were 
performed in triplicate.
UV analysis
Quantitative determination of PRX was 
performed by UV spectroscopy. The stock 
standard solution of PRX (1 mg/ml) was 
prepared by dissolving the drug in ethanol 
and storing at 4 °C. A standard calibration 
curve (peak area of PRX vs. known drug 
concentration) was built up using standard 
solutions (0.5–100 µg/ml) prepared by 
dilution of the stock standard solution with 
ethanol. Calibration graphs were plotted 
according to the linear regression analysis, 
which gave a correlation coefficient 
value (R) of 0.999. Sample preparation 
and analyses were performed at room 
temperature.
Particle size measurement
The average diameter and polydispersity 
index (PI) of the nanocrystals were 
determined by photon correlation 
spectroscopy (PCS) using a Zetasizer 
nano (Malvern Instrument, UK). Samples 
were backscattered by a helium–neon 
laser (633 nm) at an angle of 173° and a 
constant temperature of 25 °C. The PI was 
used as a measure of the width of the size 
distribution. Zeta potential was estimated 
using the Zetasizer nano by means of the 
M3-PALS (Phase Analysis Light Scattering) 
technique, which measures the particle 
electrophoretic mobility in a thermostated 
cell. All the samples were analyzed 24 h 
after their preparation.
Statistical analysis of data
Data analysis was carried out with the 
software package R, version 2.10.1. Results 
are expressed as the mean ± standard 
deviation. Multiple comparisons of means 
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(Tukey test) were used to substantiate 
statistical differences between groups, while 
Student’s t-test was used for comparison 
between two samples. Significance was 
tested at the 0.05 level of probability (p).
Results and discussion 
Bulk PRX characterization
As previously reported, all the crystalline 
piroxicam forms were prepared and 
characterized by XRPD, FTIR and DSC 
(Lai et al., 2011). A clear identification of 
the PRX polymorphs is achieved by XRPD 
in the range between 3° and 40° 2Ɵ. In 
fact, form I shows intense diffraction 
peaks at 8.58°, 17.66°and 27.36° (2 Ɵ); 
form II at 8.94° and 38.22° (2 Ɵ); form 
III at 8.70° and 12.66° (2 Ɵ), while only 
the monohydrate form exhibits a peak 
at 26.08° (2 Ɵ). Piroxicam (polymorphs 
and monohydrate) FTIR spectra exhibit 
significant differences in the range between 
3400 and 3300 cm_1 where bands for OH 
and NH stretchings can be found, and in 
the 1700–1100 cm_1 range in which there 
are C=O, C=N, SO2 (asymmetric and 
symmetric) stretchings. DSC analysis of 
form I shows a melting point at 203°C, 
while the thermal behavior of form II 
shows an endothermic peak at 201°C with 
a shoulder at 202°C. Form III melting 
point is 202°C and the monohydrate 
shows an endothermic peak at 131°C, 
corresponding to the loss of water, 
followed by another endothermic peak 
at 202°C. The comparison of each PRX 
polymorph analytical data with those of 
bulk PRX allowed us to confirm that the 
utilized commercial piroxicam presents a 
crystalline form which agrees with form I.
Nanosuspension and ODT 
preparation and particle size 
measurement 
In a previous article we produced different 
formulations of PRX nanosuspensions 
(water suspension of PRX nanocrystals) 
by HPH using bulk PRX and different 
amounts of poloxamer 188 as stabilizer. 
In this work, to formulate the ODTs, we 
selected the nanosuspension with 1.5% 
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of poloxamer 188 (calculated as % in the 
final ODT formulation) that had shown 
the lowest PCS average diameter. Selected 
operational conditions for nanosuspensions 
preparation were 30 homogenization cycles 
at 1500 bar, which were proceeded by 3 
cycles at 500 bar as a kind of pre-milling. 
PRX nanocrystals PCS diameter (Z-AVE) 
and Z potential were respectively 414 nm 
(0.40 PI) and -18.1±0.4 mV, determined 
just 24 h after the last homogenization 
cycle. ODT are dried products of a water-
soluble mixture with drug. The liquid 
nanosuspension was transformed into 
ODT by means of the lyophilisation 
method using different components as 
excipients (PEG4000, maltodextrins and 
xanthan gum or gelatin or crosscaramellose, 
table 1) (Thakur and Kashi, 2011). The 
mixture of the water-soluble excipients and 
the drug nanosuspension was placed in 
blister pockets and freeze-dried to remove 
the water by sublimation (seen section 2). 
Different cryoprotectants, typically water-
soluble sugars, have been generally added to 
the nanosuspension prior to lyophilisation 
to protect them from freezing damage, 
due to ice formation, and to minimise the 
particle size growth during lyophilisation 
(Van Eerdenbrugh et al., 2008). As 
previously reported, the presence of the 
stabilizer (poloxamer 188), used in the 
nanosuspension preparation, reduced 
PRX particle aggregation after ODT 
rehydration (Lai et al., 2011, 2009). PCS 
diameter (Z-AVE) and Z potential of PRX 
particles were determined just after ODT 
disaggregation in water (few seconds) 
and are reported in table 2. As it can be 
seen in table 2, the lyophilisation process 
little influences the PRX particle size and 
Z potential for all ODT formulation 
(Mauludin et al., 2009a).
Analytical characterization
Recently, PRX ODT and the corresponding 
coarse suspension were characterized 
by XRPD, FTIR and DSC techniques 
(Lai et al., 2011). In order to avoid the 
analytical contribute of ODT formulation 
components, nanocrystals of PRX stabilized 
by poloxamer188 were also characterized. 
Former study allowed us to establish that a 
polymorphic transition took place during 
the high pressure homogenization; the 
polymorphic transition was also evident 
by simple visual inspection: starting PRX 
bulk powder was white, conversely, the 
obtained nanosuspension and relatives 
ODT formulations showed a bright yellow 
color (Fig. 3).
In fact, in the prepared PRX nanocrystal 
ODT the presence of monohydrate 
(yellow powder)  and form III piroxicam 
mixture was proved. Since in the present 
study we prepared PRX ODT by using 
new excipients useful to improve drug 
solubility, we carried out a new analytical 
characterization, but taking into account 
ZAVE (nm)  P.I.  ZP (mV)
PRX nanocrystals  414.3± 21.1  0.40± 0.02  - 18.1± 0.4
ODT Xanthan  509.3±20.3  0.42 ±0.07  - 17.4±0. 7
ODT  Gelatin  532.5 ± 25.6  0.44 ±0.07  - 19.8 ±0.5  
ODT  Crosscaramellose  524.3 ± 19.7  0.43 ±0.09  - 21.8 ±0.3  
 
  
  
Table 2. PCS average diameter (Z-AVE), 
polydispersity index (PI) and zeta potential (ZP) 
of starting PRX nanocrystals and PRX nanocrystals 
after ODT disaggregation in water.
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I  II  III  Monohydrate  
ODT  
Xanthana
 
ODT  
croscarmellose  
ODT  
gelatin  
2t
he
ta
 
8.58  8.94  8.70  9.94  
-  
-  -  
11.62 
12.48 
13.24 
13.96 
14.42  
10.06  -  11.76  12.06(#) 12.02(#)  12.00(#)
-  -  12.66  -  
-  
-  -  
17.66  -  17.80  
13.78  
14.30  
14.82  
16.34  
-  
-  -  
-  
19.66, 
19.90, 
20.28  
18.40  -  
-  
-  -  
-  22.98  24.62  21.20  21.48(#) 21.48(#)  21.42(#)
26.72 
27.36 
27.70  
-  -  26.08  26.34(#) 26.34(#)  26.34(#)
-  -  
28.00 
28.96  
27.98  
29.52  
30.28  
28.06(^) 
28.32(^)  
28.26(^)  
29.82(#)  
27.98(#)
28.96(^)
-  38.22  -  -   -  -  
Table 3. Comparison of the 2θ degree value between 
each PRX polymorph forms and PRX nanocrystal 
ODTs, (*)=relative to form I, (^)=relative to form 
III, (#)=relative to monohydrate form
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the previously obtained results. The ODT 
diffraction patterns are not crystalline 
due to the high percentage of amorphous 
components; however, some peaks 
imputable to PRX and poloxamer (19.1° 
and 23.3° 2θ) are evident. In Table 3, 
comparison between XRPD peaks of 
piroxicam polymorphic forms and that of 
all the prepared ODT, is shown. In ODT 
formulations FTIR spectra, the poloxamer 
188 absorption bands due to OH (3400 
cm-1) and C-O stretchings (1112-1108 
cm-1) are evident. Furthermore, it can be 
also observed:  C=O stretching in the range 
1643-1633 cm-1, OH bending typical of 
monohydrate form at 1602 cm-1, C=N 
stretching in the range 1556-1530 cm-1, 
SO2 asymmetric stretching in the range 
1354 and 1331 cm-1 and SO2 symmetric 
stretching at 1151 cm-1.
Moreover, in the region between 3600 
and 3200 cm-1, the croscarmellose ODT 
spectrum showed also a peak at 3343 
cm-1 characteristic of PRX form III N-H 
stretching (Table 4), overlapped to the 
large OH stretching. As in the previously 
studied ODT, the XRPD and FTIR 
analyses allowed us to confirm the presence 
of monohydrate and form III mixture in 
the new ODT. 
The thermal behavior of bulk piroxicam 
shows an onset temperature of 202°C 
and a melting peak at 203°C while 
poloxamer 188 onset temperature is at 
51°C and the melting peak at 55°C. Due 
to their amorphous state, all the ODT 
thermograms do not exhibit significant 
thermal events besides that belonging 
to poloxamer. The solid state of PRX 
commercial ODT (Feldene Fast®) was also 
investigate. As shown in the 4000-2800 
cm1 and 1700-1100 cm-1 regions reported 
in figure 4, bulk PRX (Form I) and Feldene 
FTIR spectra are compared. In commercial 
ODT, the NH stretching at 3338 cm-1 and 
the absence of the absorption band at 1602 
cm-1 (characteristic of monohydrate form) 
suggested the presence of bulk PRX form I. 
Due to the amorphous diffraction pattern 
of Feldene and ODT, a XPRD study is not 
significant.
In vitro dissolution studies
Drugs like PRX (Biopharmaceutics 
Classification System class II drugs), 
characterized by poor solubility and high 
permeability, show an oral absorption rate 
strongly dependent on dissolution rate. In 
order to achieve superior dissolution rate 
and, therefore, higher oral absorption, in 
this work we prepared three ODTs (starting 
from the same nanosuspension and 
containing PEG4000 and maltodextrins), 
which differed each other for the nature of 
only one excipient: xanthan gum or gelatin 
or croscarmellose. To study the influence 
of these different excipients on the PRX 
dissolution properties, dissolution tests 
were performed in distilled water according 
	  
Fig. 3. White bulk powder PRX ODT (left) and 
bright yellow ODT with PRX nanosuspension 
(right)
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 Form I  Form II  Form III  Monohydrate  ODT 
xanthana  
ODT  
croscarmellose 
ODT
Gelatin
 OH  -  -  -  3451  3391  3411  3041  
 NH  3338  3393  
3343
 
3323
 
3377  Overlapped 
with  OH  
3343  Overlapped 
with  OH
 C=O  1630  1642  1634  1642  1643  1633  1643  
 OH  -  -  -  1599  1602  1607  1602  
 C=N  1530  1530  1531  Overlapped 
with  OH
 
1531  1534  1553  
 SO 2 as.  1351  1354  1354  1331  1332  1332  1332  
 SO 2 s.  1181  1180  1184  1160  1152  1150  1151  
 
  
  
%
 T
1700 1600
a
b
1500 1400
cm-1
1300 1200 1100
%
 T
4000 3800
a
b
3600 3400
cm-1
3200 3000 2800
Table  4. Comparison of the 2q degree value between 
each PRX polymorph forms and PRX nanocrystal 
ODTs, (*)=relative to form I, (^)=relative to form 
III, (#)=relative to monohydrate form
Fig. 4. FTIR spectra comparison (4000-2800 cm-1 
and 1700-1100 cm-1 regions) PRX (Form I) and 
Feldene
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to the United States Pharmacopeia 
(Figure 5 a-d) (Ambrogi et al., 2007) 
(Tantishaiyakul et al., 1999). Dissolution 
rate of the PRX nanosuspension ODT 
was compared with those of PRX coarse 
suspension ODT, PRX/poloxamer 188 
physical mixture, bulk PRX samples and 
a PRX commercial ODT (Feldene Fast®). 
All samples contained 20 mg of PRX. 
Very similar dissolution profiles for bulk 
and physical mixture were obtained since, 
as previously shown, the presence of the 
surfactant at the tested concentration did 
not increase the PRX solubility (Lai et al., 
2011). ODT formulations prepared using 
coarse PRX showed a faster release than 
bulk PRX and physical mixture of PRX/
poloxamer 188. To elucidate this result, 
we performed a study on the variation of 
the PRX solubility using the same PRX/
excipient ratio as in the ODT formulation. 
Addition of PEG4000, poloxamer 188, 
xanthan gum or croscarmellose did not 
give any significant variation of the PRX 
solubility. By contrast, the addition of 
maltodextrin or gelatin determined, 
respectively, a little (17.02 ± 0.45 mg/l) or 
great increase in the PRX solubility (94.78 
± 2.38 mg/l, Table 5). PRX solubility 
was also determined in citric acid and/
or aspartame and/or mannitol water 
solutions because these are the excipients, 
together with gelatin, of the commercial 
PRX formulation Feldene Fast® (Table 5). 
Since the amount of every Feldene Fast® 
component is not precisely known, we 
prepared these solutions with the same 
PRX:excipient ratios reported in Zydis 
patent, where the preparation procedure 
of PRX ODT is reported (Owen et al., 
2000). PRX coarse suspension ODT with 
xanthan gum did not reach the dissolution 
rate of the same ODT prepared with 
gelatin or croscarmellose (figure 5 a-c). 
This result can be due to the fact that 
croscarmellose is a super disgregant and 
that the PRX solubility is significantly 
increased by the presence of gelatin. 
Nevertheless, all ODT formulations 
prepared using PRX nanocrystals showed 
a drug dissolution rate higher than ODT 
prepared using coarse PRX. As previously 
demonstrated by XRPD and FTIR studies, 
the homogenization process led to a 
polymorphic transition from the form I 
(bulk commercial PRX) to the form III 
and monohydrate form nanocrystals. 
Indeed, this is because homogenization 
generates high energetic forces, which lead 
not only to drug particle break down to 
the nanometer range but also to a change 
in crystal structure (i.e., partial or total 
amorphisation) that could further enhance 
the solubility (R.H. Muller et al., 2003). 
Probably, the main reason of this behavior 
could be the consequence of the particle 
dissolution followed by recrystallization. 
However, in this study, the solubility of 
the different PRX polymorphic forms 
 
  
  
 Solubility mg/l  
PRX (form I)  14.33 ± 0.60  
PRX/Maltodextrin  17.02 ± 0.45  
PRX/Gelatin  94 . 78 ± 2 . 38  
Feldene Fast ®  184. 09 ±4.68  
PRX/Mannitol  55 . 34 ± 1 . 49  
PRX/Aspartame  58. 36 ±2 . 09  
PRX/Citric Acid  54 . 89 ± 2 . 12  
Prx+Mannitol+ CitricAcid  58 . 21 ± 2 . 52  
Table 5. PRX solubility in different ODT excipients 
water solutions
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increased only slightly from bulk PRX 
(form I) to monohydrate, to form II and to 
form III (Table 6).
Therefore, the variation of the PRX 
polymorphic form was not the factor 
responsible for the higher dissolution rate 
of ODT nanocrystals or, at least, it was not 
the most important one. So, we have to 
conclude that, as predicted in the Noyes–
Whitney (Noyes and Whitney, 1897) 
dissolution model, the improvement in 
piroxicam dissolution rate was mainly 
caused by the increased surface-to-volume 
ratio due to the submicron dimension of 
the drug particles (Kocbek et al., 2006) 
(Lai et al., 2011) (Mauludin et al., 
2009b). Dissolution rate of the different 
PRX nanocrystal ODT formulations 
was also compared with that of the 
commercial formulation Feldene Fast®. 
The PCS diameter (Z-AVE) of PRX 
particles determined just after Feldene Fast® 
disaggregation in water (few seconds) is 
1482 nm (0,92 P.I), a value higher than that 
of PRX obtained from ODT formulation 
(xanthan, gelatin, croscarmellose) (Table 
2). Xantan gum containing PRX ODT 
showed a very interesting dissolution 
profile, but slower than that of Feldene 
Fast® (figure 5d). This behavior can be 
explained considering the great increase of 
PRX solubility in the presence of gelatin (a 
Feldene Fast® excipient).
Both gelatin-ODT and, especially, 
croscarmellose-ODT showed a dissolution 
profile much faster than the commercial 
formulation (figure 5d). In particular, it 
can be noticed that after five minutes, 
the amount of PRX dissolved from both 
gelatin- or croscarmellose-ODT was 
almost twofold higher than Feldene Fast®, 
with dissolution rate from croscarmellose-
containing formulation a little bit higher 
than the gelatin-ODT. 
ODTs are designed to easily and rapidly 
disintegrate in the oral cavity rather than to 
be swallowed whole. In this way, the faster 
drug dissolution in the mouth might be 
enhanced leading to promoted absorption 
through the oral mucosa. This is a very 
important point since the aim of this 
work was to prepare formulations capable 
of improving oral mucosa piroxicam 
absorption for a rapid systemic distribution 
bypassing the gastrointestinal tract. 
These interesting data can be explained 
by different mechanisms. In the case of 
croscarmellose-ODT the higher dissolution 
rate compared to that of the commercial 
formulation is determined by the good 
disgregant activity of croscarmellose that 
allows the ODT quick break up with 
consequent release of the submicron sized 
PRX particles with an increased surface-
to-volume ratio.  Gelatin-ODT, like 
Feldene Fast®, showed an improved PRX 
solubility due to the presence of gelatin. 
Therefore, in this case, the increased PRX 
dissolution rate in comparison with the 
 
  
  
PRX polymorphic form
 
Solubility (mg/l)  
Form I ( Bulk PRX)  14.33±0.60  
Form II  16.72±1.50  
Form III  16.98±2.09  
Monohydrate Form  16.52±1.25  
Table 6. PRX polymorphic form solubility in water
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commercial formulation can be only 
ascribed to the increased drug surface area 
due to the nanosize of the PRX particles. 
In conclusion, results of this work confirm 
that the improvement of PRX dissolution 
rate using ODT is mainly caused by the 
increased surface-to-volume ratio due to 
the submicron dimension of the drug 
particles (Kocbek et al., 2006; Lai et al., 
2011; Mauludin et al., 2009b). However, 
a further important result obtained here 
emphasizes the importance of the proper 
choice of ODT excipients.
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a - Xanthan
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PRX nanosuspension ODT (Xanthan)
Coarse PRX ODT (Xanthan)
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Fig. 5a. Dissolution profile of xanthan-ODT 
prepared using PRX coarse and PRX nanocrystals 
compared to those of bulk PRX, PRX/poloxamer 
188 physical mixture and commercial formulation 
Feldene Fast
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b - Gelatin
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Fig. 5b. Dissolution profile of gelatin-ODT 
prepared using PRX coarse and PRX nanocrystals 
compared to those of bulk PRX, PRX/poloxamer 
188 physical mixture and commercial formulation 
Feldene Fast
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c - Croscarmellose
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PRX nanosuspension ODT (Croscarmellose)
Coarse PRX ODT (Croscarmellose)
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Fig. 5c. Dissolution profile of croscaramellose-ODT 
prepared using PRX coarse and PRX nanocrystals 
compared to those of bulk PRX, PRX/poloxamer 
188 physical mixture and commercial formulation 
Feldene Fast
95
d
20
15
10
5
0 20 40 60
time (min)
80 100 120
PRX nanosuspension ODT (Xanthan)
PRX nanosuspension ODT (Gelatin)
PRX nanosuspension ODT (Croscarmellose)
Feldene Fast
m
g/
l P
R
X
Fig. 5d. Dissolution profile of crosscaramellose, 
gelatin and xanthan-ODT prepared using PRX 
nanocrystals compared to a commercial formulation 
Feldene Fast
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Formulation 
and evaluation 
of quercetin 
nanosuspension 
incorporated 
maltodextrin fast - 
dissolving films 
Introduction
Quercetin (3,3,4,5,7 - pentahydroxyflavone, 
Que, Fig. 1), one of the most common 
dietary polyphenol widely found in plant 
kingdom including vegetables, fruits, herb 
medicine and red wine, has been intensively 
investigated for its anti-inflammatory, 
antioxidant, antiviral, and anticarcinogenic 
properties for various animal and human 
ailments (Askari et al., 2013) (Date et al., 
2011) (Ekström et al., 2011) (Cui et al., 
2008) without any evidences of toxicity, 
carcinogenicity and genotoxicity related to 
consumption (Ruiz et al., 2009) (Utesch 
et al., 2008) (Harwood et al., 2007). 
In the western world, the average daily 
intake of quercetin has been estimated to 
be between 20 mg and 40 mg, although 
it can increase up to 500 mg/day in 
individuals who ingest large quantities of 
apples, onions and tomatoes (Manach et 
al., 2005) (Manach et al., 2004) (Russo 
et al., 2012). However, the poor water 
solubility, short biological half-life, and low 
oral bioavailability of quercetin hampered 
its application as a therapeutic agent 
(Khaled et al., 2003) (Hollman et al., 
1996) (Gugler et al., 1975). Although the 
increased dissolution has been reported to 
significantly enhance both bioavailability 
and clinical effects of quercetin (Khaled 
et al., 2003), the relatively high molecular 
weight with high melting point and low 
water-solubility still present the main 
challenges for improving its solubility 
characteristics (Pool et al., 2013). 
Fast-dissolving oral delivery systems are 
solid dosage forms, which disintegrate or 
dissolve in few minutes when placed in 
the mouth without drinking or chewing. 
The first developed fast-dissolving dosage 
form consisted in tablet form, and the 
rapid disintegrating properties were 
obtained through a special process or 
formulation modifications (Sandri et 
Fig.1 Quercetin structure
OHO
OH
OH
OH
OH O
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al., n.d.). More recently, fast-dissolving 
films are gaining interest as an alternative 
to fast-dissolving tablets to definitely 
eliminate patient’s fear of chocking and 
overcome patient impediments. Fast-
dissolving films are generally constituted 
of plasticized hydrocolloids or blends made 
of this compounds that can be laminated 
by solvent casting or hot-melt extrusion. 
According to the film forming material 
characteristics, the manufacture of the 
dosage forms can present different critical 
issues. Common problems are caused by 
foaming during the film formation due 
to the heating of the material or solvent 
evaporation, the flaking during the slitting 
and the cracking in the cutting phase. 
Furthermore, the films should be stable to 
moisture overtime. Finally, to facilitate the 
handling they have to be flexible and exhibit 
a suitable tensile stress and do not stick to 
the packaging materials and fingers. The 
first material employed to produce edible 
films was pullulan, a glucan consisting of 
maltotriose units, produced from starch 
by the fungus Aureobasidium pullulans 
(Leathers, 2003). Even if pullulan-
based films are easily manufactured, the 
use of this material is limited by the low 
availability and high costs. Therefore, in 
the last years other edible hydrocolloids 
have been studied as substitute. The 
film-forming properties of modified 
starches, gums, cellulose ethers, alginates, 
polyvinylalcohols, polyvinylpyrrolidones 
or blends thereof have been consider 
(Mashru et al., 2005). Among them, 
maltodextrins (MDX) with a low dextrose 
equivalent (DE) were proposed to improve 
the flexibility and reduce the cracking of 
modified starch-based films. Nevertheless, 
the application of MDX as the main 
film forming material has been scantily 
investigated (Shamekh et al., 2002) and, 
to our knowledge, no information about 
the effect of plasticizers on their tensile 
properties has been reported.
The aim of this work was to investigate the 
possible use of maltodextrin IT6 (MDX) 
to prepare fast-dissolving films, loaded 
by quercetin nanocrystals. Quercetin 
nanosuspensions (Qn) were prepared using 
an high pressure homogenizer, meanwhile 
drug loaded films were obtained drying 
in a siliconized polyester sheet Qn with 
the others compounds in a oven at 60 
°C. Films were finally cut and packed 
within sealed aluminium pouches. Qn 
were characterized by photo correlation 
spectroscopy for mean size and size 
distribution and by transmission electron 
microscopy for morphological studies. 
On the other hand, Qn loaded films were 
characterized in term of flexibility, tensile 
strength and thickness.
Finally, dissolution studies in distilled water 
were performed, comparing release profiles 
of quercetin loaded films, quercetin raw 
material and Qn.
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Materials and methods
Materials
Maltodextrin having a D.E. equal to 
6 (Glucidex® IT6, MDX6) was kindly 
obtained by Roquette, (F). Glycerin (GLY) 
and sorbitan monooleate (Span® 80, S80) 
were purchased from Carlo Erba Reagenti 
(I) and Croda (E), respectively. Polysorbate 
80 (Tween® 80) was purchased from 
Galeno and Quercetin (≥95%, HPLC, 
solid) was purchased from Sigma-Aldrich. 
All solvents were of analytic grade, unless 
specified.
Quercetin nanosuspension 
preparation
Quercetin nanosuspensions was prepared 
by high pressure homogenization. 5% 
(w/w) Que coarse powder was dispersed 
in water with 1% (w/w) of Tween 80 
and disintegrated into microparticles by 
a high shear homogenizer (Ultra-Turrax® 
T25, IKA, Germany) at 12,000 rpm for 
5 min. Obtained microsuspension was 
homogenized at high pressure using a high 
pressure homogenizer (EmulsiFlex-C5, 
Avestin Inc., Ottawa, Canada). At first, 5 
cycles at 500 bar were conducted as pre-
milling step, and then 20 cycles at 1000 bar 
were run to obtain the nanosuspensions.
Particle size and zeta potential 
measurements
Quercetin nanosuspensions were analyzed 
for particle size and zeta potential by photon 
correlation spectroscopy (PCS) using a 
Zetasizer Nano ZS (Malvern Instruments, 
UK). Samples were backscattered by a 
helium–neon laser (633 nm) at an angle 
of 173° and a constant temperature of 
25°C. The instrument systematically and 
automatically adapts to the sample by 
adjusting the intensity of the laser and 
the attenuator of the photomultiplier, 
thus ensuring reproducibility of the 
experimental measurement conditions. 
Zeta potential was estimated using the 
Zetasizer nano-ZS by means of the M3-
PALS (Phase Analysis Light Scattering) 
technique. All the samples were analyzed 
24 h after their preparation. A long-term 
stability study of formulations stored at 
4 ± 1°C was performed by monitoring 
formulations average size, polydispersity, 
and surface charge over 90 days. The 
presence of possible aggregated was 
investigated by using an Accusizer 770 
granulometer (P SS Inc., Santa Barbara, 
USA). The results are expressed as the 
mean of three determinations.
Film preparation
Films were prepared modifying the solvent 
casting technique previously described 
(Cilurzo et al., 2008). Briefly, drug loaded 
film was obtained by gradually adding 
MDX6 to a quercetin nanosuspension. 
Afterwards, GLY and S80 were added in 
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the specific proportion (Table 1). After a 
rest period of at least 24h, slurries were cast 
over a silicone release liner by a laboratory-
coating unit Mathis LTE-S(M) (CH). 
Operative conditions: coating rate: 1 m/
min; drying temperature: 50 °C; drying 
time: 20 min; air circulation speed: 1200 
rpm. These conditions were set to obtain 
films having a thickness of about 120 µm 
(MI 1000 micrometer, ChemInstruments, 
USA). Film was cut into suitable shape 
and size as required for testing, packed 
immediately after the preparation in 
individual airtight aluminum seal packs 
and stored at 25 °C until use. Placebo 
film was also prepared following the same 
procedure. 
Film thickness
Film thickness was measured by using a MI 
1000 µm (ChemInstruments, USA). The 
accuracy of the instrument was 2.5 µm ± 
0.5%. A 10 x 2.5 cm sample of the film was 
placed between the anvil and the presser 
foot of the micrometer, and its thickness 
was measured in ten different positions. 
The determination was performed in 
triplicate.
 Film flexibility
The film flexibility was determined by 
adapting the ASTM bend mandrel test 
(D 4338-97). Briefly, a 2 x 3 cm sample 
was bended over an 8 mm mandrel and 
examined for cracks over the area of 
the bend in a strong light. The film was 
assumed as flexible if no cracks were visible 
at a 5x magnification.
Tensile properties
Tensile testing was conducted using a 
texture analyzer AG/MC1 (Acquati, I), 
equipped with a 5N load cell. The film 
was cut into 100 x 12.5 mm strips and 
equilibrated at 25 °C for 1 week. Tensile 
tests were performed according to ASTM 
International Test Method for Thin Plastic 
Sheeting (D 882-02). Each test strip was 
longitudinal placed in the tensile grips on 
the texture analyzer. Initial grip separation 
was 60 mm and crosshead speed was 
500 mm min-1. The test was considered 
concluded at the film break. Tensile 
strength, elongation at break, elastic 
modulus and tensile energy to break were 
computed to evaluate the tensile properties 
of the films. Tensile strength (TS) was 
calculated by dividing the maximum load 
by the original cross-sectional area of the 
specimen and it was expressed in force 
per unit area (MPa). Percent elongation 
at break (E%) was calculated by dividing 
the extension at the moment of rupture 
of the specimen by the initial gage length 
of the specimen and multiplying by 100 
according to the following equation:
 E% = L - L0 / L0 x100
where L0 is the initial gage length of 
the specimen and L is the length at the 
Ingredient  
Composition (%, w/w)  
Drug loaded lm
 
Placebo lm  
Quercetin  4.98  -  
MDX6  71.18  74.91  
GLY  20.00  21.06  
S80  2.84  2.99  
TWEEN80  1.00  1.05  
 
  
  
Table 1. Composition of placebo and quercentin 
loaded film
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moment of rupture. Elastic modulus or 
Young’s modulus (M) was calculated as the 
slope of the linear portion of the stress–
strain curve. The result was expressed in 
force per unit area (MPa). Tensile energy to 
break (TBE) was defined by the area under 
the stress–strain curve. The value is in units 
of energy per unit volume of the specimen’s 
initial gage region. The result was expressed 
in energy per unit volume. An average of 
five measurements was taken for each type 
of specimen.
Transmission electron 
microscopy (TEM)
Characterization of the external 
morphology of Qn, placebo film and 
Qn loaded film was determined using 
transmission electron microscopy (TEM). 
For nanosuspensions, a drop of preparation 
and an equal volume of an aqueous 1% 
uranyl acetate solution were adsorbed on 
the surface of copper grid and dried at 
room temperature for 24 h. The sample 
was transferred into a TEM (Tecnai 12, 
FEI) operating at 120 kV. Placebo film 
and Qn loaded film, instead, were put in 
an aluminum stub without any reagent and 
then analyzed with the same instrument.
In vitro dissolution studies
In vitro dissolution studies on quercetin 
raw material, Qn and Qn loaded film were 
performed according to the United States 
Pharmacopeia (USP) using the rotating 
basket method (Erweka apparatus). The 
dissolution media was 1000 ml of distilled 
water kept at 37 ± 0.1 °C and a rotation 
speed of 100 ± 2 rpm. At preselected time 
intervals, 1 ml samples was withdrawn 
(replaced with 1 ml of pre-thermostated 
fresh dissolution medium), filtered 
through polycarbonate membranes (0.45 
µm, Millipore) and analysed by HPLC at 
367 nm, using a chromatograph Alliance 
2690 (Waters, Milan, Italy). The column 
was a SunFire C18 (3.5m, 4.6 x 150 
mm). The mobile phase was a mixture 
of acetonitrile, water and acetic acid 
(94.8:5:0.2, v/v), delivered at a flow rate of 1.0 
ml min-1. Dissolution tests were performed 
in triplicate.
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Results and discussion
This work aimed to study maltodextrins 
(MDX) with a low dextrose equivalent as 
film forming material and their application 
in the design of oral fast-dissolving film 
loaded with quercetin nanosuspensions.
Qn were characterized in PCS diameter 
(Z-AVE), polydispersity index (PI) and Z 
potential just after preparation. Data are 
reported in Table 2. A long time stability 
studies was carried out by measuring the 
same parameters of Qn stored at 4 ± 1 °C 
for 90 days. Freshly prepared Qn presented 
a Z-AVE of 753 nm (0.31 PI) and a Z 
potential of −51,7 mV. This very highly 
negative zeta potential values should ensure 
high stability against the possibility of a re-
aggregation phenomena. As shown in the 
Table 2, during the first 30 days, quercetin 
nanosuspensions maintained similar mean 
diameter and polydispersity index values. 
However, after two months of storage, the 
dimension and the polidispersity index 
slightly increased,  reaching 851 nm and 
0,45 respectively at 90 days. During the 
checked three months, the Z potential 
values were constant. Qn PCS diameter 
was confirmed by TEM images (Fig. 2).
TEM images of quercetin nanosuspensions 
loaded film and placebo film are showed 
in figure 3a-b. Qn loaded film (fig. 3a) 
disclosed a rough surface and showed, 
mixed with film matrix, several quercetin 
nanocrystals arranged in different position 
and orientation. An other feature easily 
recognizable in figure 3a is the porosity 
of the film. On the other hand, figure 3b 
showed TEM images of placebo film. In 
this case is well visible only the porosity of 
the film, meanwhile there are not traces of 
the surface roughness of Qn loaded film, 
probably due to the presence of quercetin 
nanocrystals.
Since critical issues in the development of 
a fast-dissolving film are mainly related to 
its mechanical properties, different studies 
were carried out. In particular, flexibility 
and tensile strength were evaluated for 
both Qn loaded film and placebo film. 
In a previous work (Cilurzo et al., 2008), 
particular attention was given to the 
selection of a proper plasticizer able to 
provide a suitable ductility and flexibility 
to MDX films under different types of 
mechanical stress. PEG 400 as well as the 
esters of citric acid was excluded because 
of the lack of miscibility with MDX. 
Satisfactory results were obtained adding 
both glycerol (GLY) and propylene glycol 
(PG) to MDX at different concentrations 
(16-18-20-22% w/w). In particular 
flexible films were obtained at GLY or PG 
content of at least 16% w/w or 18% w/w, 
respectively. Films prepared by using GLY 
or PG amount higher than 20% or 22% 
w/w, respectively, resulted too ductile for 
handling. Normally, the increase of the 
plasticizer content caused a decrease of the 
 
  
  
Qn  5%  MD (nm)  P.I.  ZP (mV)  
Day 0  753 ±8,2  0,31 ± 0,05  - 51,7 ± 1, 3  
Day 1  752 ±1,2  0,33 ± 0,03  - 49,4 ± 0,8  
Day7  761±3,3  0,30 ± 0,07  - 50,7 ± 0,1  
Day14  757 ±5,7  0,36 ± 0,06  - 47,9 ± 1,0  
Day30  783±15  0,38 ± 0,02  - 52,8 ± 1, 3  
Day60  843± 4,6  0,42 ± 0,02  - 48,6 ± 0,9  
Day90  851 ± 3,2  0,45 ± 0,02  - 49,5 ± 1, 6  
Table 2. Mean size (Z-AVE), polydispersity 
index (PI) and Z potential (ZP) of quercetin 
nanosuspensions  stored at 4 ± 1 °C and monitored 
during 90-day
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Fig. 2. Quercetin nanosuspension TEM images
Fig. 3a-3b. Quercetin nanosuspensions loaded 
film (3a) and placebo film (3b)
Table 3. Thickness and tensile properties of the films
 
  
  
 ickness (µm)
 
E%  TS (MPa)  EM (MPa)  TBE (J)  
Placebo lm  128±3  106,9±10,8  5,24±0,33  1,29±0,12  0,356±0,017
Qn loaded 
lm  
204±1  9,6±0,4  0,65±0,04  0,14±0,00  0,008±0,001
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elastic modulus (EM), which is an index 
of stiffness, and the tensile stress (TS). The 
ductility, that is expressed as elongation 
at break (E%), increased increasing 
the plasticizer amount. The toughness, 
expressed as the tensile energy to break 
(TBE), resulted reduced only at the highest 
concentration of GLY. On the basis of 
this previous results, GLY was chosen as 
the suitable plasticizer for MDX and the 
concentration at 20% w/w was selected to 
formulate and produce both MDX placebo 
fast-dissolving films and MDX-Qn loaded 
fast-dissolving films by a modified casting 
technologies.  Moreover, the addition of 
a surfactant agent was necessary. Benefits 
were achieved by adding surfactants with 
a low HLB value. The addition of sorbitan 
oleate 80 (S80) at 2,84% in Qn loaded 
film and 2,99% in placebo film caused a 
slight increase of stiffness. The addition 
of quercetin nanosuspensions to the basic 
formulations did not compromise the 
film preparation. Indeed, all films resulted 
flexible and appeared homogeneous and 
pale yellow. The values of thickness and 
the film tensile properties are reported in 
Table 3. 
Film thickness (128 µm for placebo film 
and 203 µm for Qn loaded film) was 
not very homogeneous probably due to 
the shrinkage of the mixture spread on 
the silicone release liner selected for the 
preparation by casting. The presence of 
the drug significantly modified the tensile 
properties of the film, determining a 
relevant decrease in the elastic modulus 
(EM= 0,14 for Qn loaded film; EM= 1,29 
for placebo film) and in consequence an 
increase of the film stiffness. Results showed 
in table 3 confirmed that the dispersion 
of drug crystals (although in nano-meter 
range) to a film determines an increase of 
the film fragility, in fact also E% (9,6% 
against 106,9%), TS (0,65 MPa against 
5,24 MPa) and TBE (0,008 J against 
0,356 J) show an important decrease when 
the film are prepared adding quercetin 
nanosuspensions. This phenomena is 
probably due at a less homogenous 
interaction between the film matrix 
compounds when drug nano crystals are 
presents. Despite that, the formulations 
maintained satisfactory flexibility and 
resistance to elongation for the production 
and packaging.
To study the influence of different 
formulations on the Que dissolution 
properties, dissolution tests were 
performed in distilled water according to 
the United States Pharmacopeia. The in 
vitro release profiles of quercetin loaded 
film were compared to those of quercetin 
raw material and Qn  (Fig. 4). 
All tested samples contained 10 mg of Que. 
Qn loaded film showed a dissolution profile 
faster than quercetin nanosuspensions 
and quercetin raw material. In particular, 
it can be noticed that after five minutes, 
Fig 4. Dissolution profiles of quercetin loaded 
film, quercetin raw material and quercetin 
nanosuspensions (Qn)
0
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the amount of Que dissolved from Qn 
loaded film, quercetin nanosuspensions 
and quercetin raw material was 72.73%, 
54.00% and 11,34% respectively.
The increased surface-to-volume ratio due 
to the submicron dimension of the drug 
particles can explain the faster dissolution 
profiles of quercetin nanosuspensions and 
Qn loaded film compared with Que raw 
material. 
Meanwhile, the better dissolution profile of 
Qn loaded film compared to the quercetin 
nanosuspensions, was probably due to the 
increased quercetin solubility determined 
by the presence of film components.
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